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Abstract 
Novel fluorogenic enzyme substrates were synthesized by the coupling of 6-
hydrazinobenz[de]isoquinoline-1,3-diones with β-alanine for the detection of β-alanyl 
aminopeptidase-producing Pseudomonas aeruginosa. A secondary reaction was also 
utilized involving the condensation of the 6-hydrazinobenz[de]isoquinoline-1,3-diones 
with a range of aryl aldehydes to give the corresponding hydrazones as a means for 
obtaining more favourable fluorescence properties. The photophysical properties of the 
synthesized hydrazines and their hydrazide and hydrazone derivatives, were examined 
and they were also incorporated into Columbia agar in order to determine their potential 
for the detection of pathogenic bacteria. 
The synthesized hydrazides and coupled derivatives displayed good fluorescence 
properties, with an average Stokes’ shift of 67 nm. Incorporation of a secondary reaction 
with aldehydes enhanced the fluorescence properties, with the exception of hydrazones 
containing the 4-dimethylamino substituent. Hydrazones prepared from benzaldehyde 
and 4-chlorobenzaldehyde displayed greatly increased fluorescence intensity, with no 
bathochromic shift, while the hydrazones from cinnamaldehyde and p-anisealdehyde 
displayed a favourable bathochromic shift along with a slight increase in fluorescence 
intensity.  
Incorporation of the synthesized compounds into Columbia agar, however, did not have 
the expected effects, as the majority of observed fluorescence was seen to be due to the 
substrate, and not the fluorophore. A high degree of localization of fluorescence within 
bacterial cells was, however, observed, although longer chain N-substituents appeared to 
have bactericidal effects on the microorganisms tested. 
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Chapter 1 
INTRODUCTION
 2 
 
1.1 Prevalence and financial burden of pathogenic bacteria 
Pathogenic bacteria are a growing problem in the healthcare sector, with more than 
177,000 potentially preventable healthcare-associated infections (HAIs) occurring 
annually in Australia alone.1 These infections are major contributors to patient 
morbidity and mortality, prolonged hospital stays, and incur substantial costs on the 
healthcare system. 
A number of studies have been undertaken to estimate the financial cost of HAIs, and 
it is currently believed that contraction of a HAI may double the economic cost of a 
hospital stay, including the associated loss in short-term patient productivity and the 
attributable mortality of 6.1%.2 In the available literature, there is a large variance 
between these estimates due to differences in the methods used to calculate the costs. 
Some studies only assessed the expenditure by the hospital, whereas others also 
considered the overall cost to the healthcare sector as well as to the public.3 Currently, 
the mean attributable cost of an HAI is thought to be around US$13,973 - US$15,275, 
depending on the cost modeling projection used.4 
Of particular concern are drug-resistant 
organisms, which may be resistant to multiple 
classes of antibiotics, leaving little or no 
efficacious treatment options. The degree of drug 
resistance expressed by an organism can be 
classified into three main classes; multidrug-
resistant (MDR; resistant to at least three 
antimicrobial classes), extensively drug-resistant (XDR; resistant to all but two or 
fewer antimicrobial classes), and pandrug-resistant (PDR; resistant to all antimicrobial 
Figure 1.1 Diagram showing 
degrees of drug resistance and 
their relationship to each other. 
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classes), Figure 1.1.5 HAIs caused by drug-resistant organisms often require more 
expensive medications, in addition to patient isolation, and prolonged hospital stays, 6 
resulting in an excess of U$15,000 in expenditure and, on average, an additional two 
days stay in hospital.7 
In Australia, for the years 2005-2007, the estimated additional cost of methicillin-
resistant Staphylococcus aureus (MRSA) infection was A$19,881 per episode, while 
enterococci or Clostridium difficile infections were associated with an excess of 
A$19,743. Other drug-resistant infections were estimated to cost an additional 
A$12,292 per hospital episode.8  
Timely antibiotic administration is essential in the treatment of many infectious 
diseases, as any delay in the administration of antibiotics can lead to increases in 
patient mortality. For example, delaying antibiotic treatment for patients suspected of 
sepsis increases the patient mortality by 7.6% for each hour.9 Furthermore, the delay 
between a patient acquiring a multi-resistant organism and the detection thereafter can 
lead to cross-infection of other patients, causing a preventable increase in infection 
rates.6 However, this must be balanced with the need for antibiotic treatment to be 
appropriate for the infectious pathogen. If the prescribed antibiotic is inappropriate for 
the infection (as a result of empirical, rather than directed, therapy), there is an 
increased risk of subsequent MDR infections10 and a four-fold greater risk of patient 
mortality.11 
In a 2014 report by the World Health Organization (WHO), seven resistant bacteria 
were highlighted as being of international concern; Escherichia coli, Klebsiella 
pneumoniae, Staphylococcus aureus, Streptococcus pneumoniae, non-typhoidal 
Salmonella (NTS), Shigella species, and Neisseria gonorrhoe.12 These drug-resistant 
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bacteria have a significant impact on global health worldwide, in both the community 
and hospital settings. 
In the hospital setting, the major causes of drug-resistant bacterial infections were 
shown to be due to four Gram-negative and two Gram-positive organisms. These so-
called ESKAPE pathogens are comprised of Enterococcus faecium, Staphylococcus 
aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, 
and Enterobacter species.13  
As part of a six-point package introduced by the WHO on World Health Day 2011, 
the surveillance of antimicrobial resistance and antibiotic use was highlighted as a key 
cornerstone of efforts to control antimicrobial resistance. Gaps in the rapid and 
accurate diagnosis for the initiation of early, targeted therapy were noted, with an 
emphasis on the development of rapid, easy-to-use diagnostic tests which could be 
employed in resource-limited settings.14 This problem is exacerbated in Australia by 
the lack of standardization in the detection and identification when dealing with HAIs, 
differing greatly from state to state. While most healthcare facilities in Australia 
perform routine surveillance of bloodstream infections, surgical site infections, and 
multi-resistant organisms, there are still significant deficiencies in national 
surveillance and reporting programs.15 
The current National Health and Medical Research Council (NHMRC) guidelines for 
the prevention and control of infection in healthcare settings focus primarily on 
standard precautions and transmission-based precautions to help limit the impact of 
HAIs. These include elements such as effective hand hygiene, use of personal 
protective equipment, handling and disposal of sharps, environmental cleaning, and 
the reprocessing of reusable medical instruments and equipment. With regards to 
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screening and surveillance of multi-resistant organisms, the benefit of targeted active 
screening for colonized patients is highlighted. However, there is no national or 
international consensus on the most appropriate method of screening. The method of 
screening to be used is thus left to the discretion of the individual facility and it is 
recommended that this choice is based upon local epidemiology, the necessity for 
screening, and available resource factors.6 
In addition to the current infection control and hand hygiene measures, other 
approaches have also been implemented, such as antimicrobial stewardship. As 
mentioned above, the overuse and inappropriate use of antimicrobials is thought to 
contribute to the emergence and spread of drug-resistant organisms. The monitoring 
of prescription trends and  limiting the supply of antimicrobials through antimicrobial 
stewardship programs can, thus, help to reduce the incidence of overprescribing and 
the emergence of drug-resistant strains.16,17  
To address these issues in Australia, a systematic intervention approach, the National 
Antimicrobial Utilisation Surveillance Program (NAUSP) has been adopted by 
hospitals. NAUSP provides an Australian peer-group benchmark, allowing hospitals 
to compare their antimicrobial usage with similar hospitals and so identify areas 
where further investigation and analysis of drug administration may be warranted.17 
In order to address the complex needs associated with lowering the numbers of HAIs, 
the implementation of antimicrobial stewardship programs, and achieving better 
patient outcomes, there is a requirement for timely and sensitive routine screening of 
patients in order to identify those colonized or infected by multi-resistant organisms 
and so facilitate the initiation of appropriate management and treatment options. For 
example, implementation of a large-scale, universal admission screening program for 
 6 
 
MRSA in three U.S. hospitals led to a reduction in the prevalence density of MRSA, 
from 8.9 to 3.9 per 10,000 patient-days.18 
 
1.2 Pseudomonas aeruginosa 
One of the ESKAPE pathogens,13 P. aeruginosa is  an aerobic Gram-negative 
bacterium which is ubiquitous in the environment. Although P. aeruginosa is most 
commonly found in soil and water, it rarely poses a problem for healthy individuals. 
However, opportunistic infections due to this organism are common in 
immunocompromised patients, including those with severe burns, cancer, and 
conditions such as acquired immune deficiency syndrome.19 
As an opportunistic pathogen, P. aeruginosa typically causes infections of the urinary 
tract, respiratory system, skin, soft tissue, bone and joints, and gastrointestinal tract. 
Infections by P. aeruginosa are associated with an increased median duration of 
hospital stay of 7 days (from isolation of bacteria to discharge) when compared to 
non-infected patients and a daily average cost of $2059 per patient.20 
One of the major complications in the treatment of P. aeruginosa is a result of its 
ability to adapt to its surroundings by forming microcolonies which can attach to 
surfaces, producing a thick exopolysaccharide layer known as a biofilm.21 This 
biofilm contains channels to allow nutrients to circulate, while protecting the 
bacterium from antimicrobial agents. As antimicrobial agents are generally tested 
against P. aeruginosa colonies in agar, the efficacy of these agents against P. 
aeruginosa where biofilm formation has occurred will be reduced and antimicrobial 
choice can be more difficult. 22 This is of particular concern in patients with cystic 
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fibrosis as there is increased potential for persistent bacterial infections of the lungs 
and early effective treatment is important. Thus, early, rapid and sensitive detection of 
even low numbers of colony forming units (CFU) of bacteria is crucial in the 
treatment of P. aeruginosa in cystic fibrosis before biofilms have formed and resulted 
in more complicated treatment options. 
 
1.3 Detection and identification of pathogenic bacteria 
Bacteria can currently be detected and identified based upon either their phenotypic or 
genotypic properties. Conventionally, bacteria have been identified after growth and 
enrichment in media via microscopy based upon their morphological features. Over 
the years, this method has been further enhanced via the incorporation of chromogens 
and fluorogens to produce chromogenic and fluorogenic media in order to aid in the 
classification of bacteria. Molecular methods, such as polymerase-chain reaction 
(PCR), fluorescent in situ hybridization (FISH), and matrix-assisted laser 
desorption/ionization-time of flight mass spectroscopy (MALDI-TOF MS) have also 
been developed, which allow for the identification of bacteria without the need for the 
isolation and culturing of the particular bacterial strains. 
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1.3.1 Physical diagnostic techniques 
1.3.1.1 Microscopy 
Microscopy provides information on the general morphology of the cell upon which 
identification may be achieved by examining the staining, size, shape, and growth 
characteristics of bacterial colonies.  
Bacteria can classically be divided into two groups based upon their differing cell wall 
structures; Gram-positive and Gram-negative, named after Christian Gram, the 
developer of the differentiating stain technique. In the Gram stain technique, bacterial 
cells are fixed on a microscope slide and stained with a solution of crystal violet 
(purple). A solution of iodine is then used to fix the stain onto the bacterial cell wall 
and the plate is washed with an alcoholic solution to remove any unfixed crystal 
violet. As a result of their distinct cell wall structures, Gram-positive cells retain the 
crystal violet dye, while Gram-negative cells do not. A counter-stain, such as safranin 
(pink) or carbol fuchsin (red), is often also used to dye and aid visualization of all the 
bacterial cells on the plate. Hence, Gram-positive cells will appear purple and Gram-
negative cells will appear pink/red, Figure 1.2.23 
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Figure 1.2 Example of a Gram-stained mixture of Gram-positive Staphylococcus 
aureus (purple) and Gram-negative Escherichia coli (pink). Taken from 
Prescott, Harley, and Klein’s Microbiology (7th ed.).19 
 
 
Examination of the morphology of the cell also helps with the differentiation of 
bacteria. The majority of bacteria tend to grow as simple shapes, such as spheres 
(cocci), straight rods (bacilli), or ovoids. However, less common shapes can also 
form, including curved rods (vibroids) and long rigid spirals (spirochaetes). If the 
bacteria aggregate into multi-cell structures, this can also be used as a means of 
differentiation, e.g. chains (Streptococci) or clusters of cocci (Staphylococci). Certain 
bacteria are also known to possess extracellular structures which can aid in their 
identification, such as flagella, fimibriae, pili, capsules, and slime layers.23 x  
Lately, more accurate morphological differentiation and identification has been made 
possible due to the examination of intracellular structures which has been facilitated 
by the development of electron microscopy. The correct detection and identification 
of bacteria, however, is dependent on the experience of the microbiologist performing 
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the test and can be very time consuming, as it involves the culturing of bacterial 
colonies, which can take between 18-72 hours to form.24,25 
 
1.3.1.2 Chromogenic media 
As an improvement to traditional microscopy methods, chromogenic and fluorogenic 
media have also been developed to aid the detection of pathogenic bacteria during 
their growth phase. These media commonly rely upon the specific enzymatic activity 
of bacteria to help differentiate between different microorganisms. 
Chromogenic media have been widely used in clinical microbiology for the detection 
of pathogenic bacteria and are based upon the hydrolysis of non-coloured synthetic 
substrates to release a characteristic coloured compound. These substrates are formed 
through the chemical combination of a chromogenic substrate and a targeting 
molecule, Figure 1.3. Ideally, this targeting molecule is a substrate for an enzyme 
which is unique to a particular bacterium (Table 1.1) and cleavage of the targeting 
molecule liberates a chromogen which can be detected against a background of other 
non-chromogenic colonies.  
 
 
Figure 1.3 Schematic representation of the principle of chromogenic detection of 
bacteria. 
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Table 1.1 List of potential enzymatic targets for synthetic substrates (adapted 
from Orenga et al.26) 
Enzyme Class Enzyme Microorganism 
Glycosidase α-Galactosidase Salmonella 
E. coli O157:H7 
β-Galactosidase Escherichia coli 
E. coli O157:H7 
colliforms 
Staphylococcus 
saprophyticus 
VREb 
α-Glucosidase Cronobacter sakazakii 
Staphylococcus aureus 
MRSA 
VRE 
β-Glucosidase KESC 
ESBL producing 
enterobacteria 
Vibrio 
Enterococci 
VRE 
Listeria spp 
Candida kefyr, Candida 
lusitaniae, Candida 
tropicalis 
Cellobiosidase Cronobacter sakazakii 
β-Glucuronidase E. coli 
ESBL producing E. coli 
Streptococcus agalactiae 
β-Ribofuranosidase Yersinia enterocolitica 
Hexosaminidase Candida albicans, Candida 
dubliniensis 
Esterase Lipase Salmonella 
Phosphoinositide 
phospholipase C (PI-PLC) 
Listeria monocytogenes 
Phosphatidylcholine 
phospholipase C (PC-PLC)  
Bacillus 
Phosphatase S. aureus 
S. agalactiae 
Clostridium perfringens 
Candida spp. 
Arylamidase/peptidase β-Alanyl aminopeptidase Pseudomonas aeruginosa 
Miscellaneous Deoxyribonuclease S. aureus 
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The majority of these substrates in common use are based on indoxyl derivatives as 
this chromogenic moiety has shown favourable water solubility upon the enzymatic 
release of an indoxyl product, which results in the formation of an indigoid dye upon 
further oxidation, Scheme 1.1.26,27 By altering the targeting molecule to ensure the 
cleavage from the chromogen only by specific enzymes, as shown in Table 1.1, it is 
possible to specifically detect different bacterial species. 
 
Scheme 1.1 Formation and release of coloured indigo blue from chromogenic 
indoxyl substrates.28 
 
Commercially available products often contain various enzymatic substrates, in 
conjunction with other nutrients, as well as  antimicrobial agents to control growth of 
unwanted organisms and so allow the differentiation of closely related species.26 
Media that help to control and limit the growth to only selected microorganisms are 
known as selective media, Table 1.2.  These media attempt to encourage the growth of 
the microorganisms under investigation whilst inhibiting the growth of unwanted 
microorganisms through a number of mechanisms, such as the addition of antibiotics, 
removal of required amino acid nutrients, or the addition of toxic stains and colour 
indicators.23 
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Table 1.2 Examples of some commonly available selective media.23 
Name Ingredients 
Eosin-methylene blue agar 
(EMB)  
Contains eosin Y and methylene blue which are toxic to 
Gram-positive organisms 
MacConkey agar (MCK)  Contains crystal violet and bile salts which inhibit the 
growth of Gram-positive organisms  
Mannitol salt agar (MSA)  Contains 7.5% NaCl which selects for species of 
Staphylococcus and inhibits the growth of most other 
bacteria 
Hektoen enteric agar (HE)  Contains bile salts which inhibit the growth of Gram-
positive organisms 
 
In addition to being selective, many of these media are also classified as differential 
media, Table 1.3. Differential media attempt to distinguish between the bacteria of 
interest and others which may otherwise have colonies with very similar appearances 
based upon differences in their growth characteristics in specific media. These media 
usually contain preferential growth factors, different dyes, and pH indicators to help 
differentiate colonies.23 
Table 1.3 Examples of some commonly available differential media.23 
Name Ingredients 
Blood agar Contains nutrient enrichment to encourage Streptococci 
growth and  bovine heart blood, which causes 
incomplete haemolysis in α-haemolytic Streptococci and 
full haemolysis in β-haemolytic Streptococci  
Eosin-methylene blue agar 
(EMB)  
Contains lactose which can be used to differentiate 
lactose fermenting bacteria  
MacConkey agar (MCK)  Contains lactose which can be used to differentiate 
lactose fermenting bacteria  
Mannitol salt agar (MSA)  Contains mannitol which can be used to differentiate 
mannitol fermenting bacteria  
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An example of a commercially available medium is CHROMAGAR™ Staph aureus 
which is used for the detection and identification of Staphylococcus aureus. Using this 
growth medium, Staphylococcus aureus colonies appear pink to mauve, while other 
colonies appear either white, blue, or their growth is inhibited, Figure 1.4.29 
 
Figure 1.4 Colonies plated from a central venous catheter tip onto Columbia agar 
supplemented with 5% horse blood (left) and CHROMagar™ Staph 
aureus (right). Colonies were incubated for 24 h at 37 °C. Taken from 
Gaillot et al.29 
 
Currently, a range of chromogenic media are commercially available for the 
identification and diagnosis of various infections, such as urinary tract infections,30,31 
Salmonella,32,33 Staphylococcus aureus,29,34 Candida,35 group B Streptococcus,36 
Pseudomonas aeruginosa,37 MRSA,38 vancomycin-resistant Enterococci (VRE),39 
extended-spectrum β-lactamase (ESBL) producing  organisms,40 and New Delhi 
metallo-β-lactamase (NDM-1) carbapenemase-producing Enterobacteriacea.41 
Unfortunately, these tests still require the growth of full bacterial colonies and so it 
can take 24-48 hours to obtain results. 
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1.3.1.3 Fluorogenic media 
Based upon similar principles to chromogenic media, fluorogenic techniques have 
also been developed for the detection of bacteria, with an emphasis on the 
enhancement of detection sensitivity and, hence, reductions in time to identification of 
bacteria.  
The improvements in detection time offered by fluorogenic substrates are a result of 
their greater intrinsic detection sensitivity over chromogens. Perception of the 
difference between the colours released by chromogens relies upon the reflection of 
light after absorption of specific wavelengths by the chromogenic compounds. 
Fluorogens, however, display light emission upon excitation by a particular 
wavelength, and are thus, inherently easier to detect against a natural/dark 
background. Due to this phenomenon, fluorogens generally display sensitivity two 
orders of magnitude greater than that of chromogens.42 
On the other hand, as many bacteria exhibit weak fluorescence around the 400-500 
nm region, it may be difficult in certain cases to differentiate between the natural 
fluorescence of bacterial species and fluorogenic compounds. For example,  
Pseudomonas aeruginosa  releases extracellular pyoverdine (Figure 1.5), which 
fluoresces within the range of 430-530 nm, with a λmax at 455 nm.43 As such, an ideal 
fluorogenic system should display fluorescence at a wavelength distinct to the natural 
fluorophores within microorganisms in order to facilitate easier detection. 
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Figure 1.5 Chemical structure of pyoveridine PAO1 (pvd-1), one of the many 
isoforms of pyoverdine, which can be secreted by P. aeruginosa PAO1. 
Other characteristics that should also be taken into consideration for a suitable  
fluorogen for bacterial detection include adherence to cells, displayed fluorescence at 
physiological pH, any growth inhibition by the substrate, specificity towards the 
target enzyme, and emission wavelength. 
An ideal fluorogen should display localized fluorescence in order to reduce the level 
of background fluorescence and so aid in identification. When discussing the 
localization of fluorescence towards bacterial cells and colonies, the cell adherence of 
the substrate is highly important. If the cell adherence of the fluorogen is weak, the 
fluorophore may diffuse into the surrounding media, making it difficult to 
differentiate between nearby colonies. 
As most bacterial growth occurs in media at physiological pH (pH 7.4), an ideal 
fluorophore must display fluorescence around this pH. This may be a concern if the 
fluorogen is too acidic or basic, thus requiring the addition of secondary agents to 
display fluorescent properties as these secondary agents may also be inhibitory 
towards bacterial growth or differentiation. An ideal fluorogen should also have a high 
sensitivity and specificity towards the target enzyme. Sensitivity refers to the ability 
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of the fluorogen to correctly detect the targeted bacteria in samples containing the 
bacteria. Specificity refers to the ability of the fluorogen to detect only the targeted 
bacteria amongst a sample with other bacteria. A high sensitivity reduces the 
occurrence of false negative results whilst a high specificity reduces the occurrence of 
false positive results.  
The most well-known and documented fluorogen is fluorescein, Figure 1.6, which is 
characterized by bright yellow fluorescence. As a result, fluorescein derivatives were 
one of the first fluorogens to be incorporated into media for the detection of bacteria. 
For example, in 1961, Kimler used fluorescein-amine (Figure 1.6) in media to enable 
the rapid isolation and identification of Staphylococci. The fluorescence of these 
media was shown to be related to fermentation of mannitol by the Staphylococci 
colonies.44 
 
Figure 1.6 Chemical structures of fluorescein and fluorescein-amine. 
 
Today, the vast majority of fluorescent media are focused around the coumarin 
structure, Figure 1.7, with the advent of cultures containing 4-methylumbelliferone 
(4-MU) and 7-amino-4-methylcoumarin (7-AMC).  
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Figure 1.7 Chemical structures of coumarin and coumarin-derived fluorophores 4-
MU and 7-AMC. 
 
4-Methylumbelliferone (4-MU) is a fluorophore that has achieved a high level of 
usage due to its high fluorescent yield and low production cost.26,45 It is most 
commonly used in the detection of E. coli and colliforms, in food and water samples, 
through β-D-galactosidase and β-D-glucuronidase activity, respectively.30,46 4-MU 
displays pH-dependent fluorescence, with significantly increased emission intensities 
in basic environments (above pH 7.8), Scheme 1.2.47 when deprotonation of the 
phenolic OH group leads to facilitation of resonance throughout the conjugated ring 
system.  
 
Scheme 1.2 Enzymatic release of 4-MU from fluorogenic substrates and extended 
resonance of 4-MU anion.  
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Media based upon 4-MU are, therefore, required to be slightly alkaline or rely upon 
the addition of an alkaline solution to reveal fluorescence.45 Moreover, with a peak 
fluorescence emission of 457 nm,48 the fluorescence observed can often overlap with 
the natural fluorescence of many bacteria, further limiting its use. As 4-MU also has a 
tendency to diffuse away from bacterial cells, it can be difficult to localize enzymatic 
activity within the cell when testing for multiple bacteria.26 
7-Amino-4-methylcoumarin (7-AMC) does not exhibit with pH dependence, and is 
characterized by excitation and emission wavelengths of 360 nm and 430 nm 
respectively, Scheme 1.3.49 It is still hindered due to the overlap between the 
fluorescence of 7-AMC and the natural fluorescence of bacteria. It also displays 
significant diffusion into the surrounding media, making the use of 7-AMC less 
common. It is currently being used for the bacterial detection of Enterococci, targeting 
several different enzymes in these microorganisms.50 
 
Scheme 1.3 Enzymatic release and extended resonance of 7-AMC from fluorogenic 
substrates 
 
Due to the limitations of 4-MU and 7-AMC substrates, other substrates with enhanced 
fluorescent and adherence properties have recently been developed, such as ethyl 7-
hydroxycoumarin-3-carboxylate (EHC), Scheme 1.4.26,46 Through the introduction of 
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electron-withdrawing substituents on the coumarin ring, the acidic phenolic OH of 
EHC (and that of other similar coumarins) has a pKa value (~7.0) lower than that of 
unsubstituted analogues (~8.0).51 These fluorogens can therefore display fluorescence 
at more neutral pH ranges, eliminating the need for alkaline conditions.47 For 
example, media containing EHC display approximately 3-fold greater fluorescent 
intensity at pH 7.0 (after 6 hours of incubation at 37 °C) than media containing 4-
MU.46 However, the emission wavelength of EHC is still similar (around 440 nm) to 
that of 4-MU and 7-AMC, leading to the same concerns regarding overlap with the 
natural fluorescence of bacterial species.46 
 
Scheme 1.4 Formation and extended resonance of EHC from fluorogenic 
substrates.  
 
Benzothiazole derivatives represent another example of fluorogens being used to 
target several different bacteria through changing the substituent at the 2-position of 
the phenyl ring, Scheme 1.5. The majority of benzothiazole derivatives currently 
being used for bacterial detection involve an amino group in the 2-position of the 
phenyl ring to allow for ease of coupling to amino acids. By coupling L-alanine to the 
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amino group, it is possible to test for the presence of Gram-negative bacteria through 
strong blue fluorescence resulting from L-alanyl aminopeptidase activity.52 
Interestingly, if a β-alanine is used instead, strong yellow fluorescence can be seen 
instead with colonies of E. coli, S. marcescens, P. aeruginosa, and Morganella 
morganii, with inhibition of other Gram-negative bacteria.52 A similar test can also be 
conducted to test for the presence of Gram-negative bacteria if a nitro group is present 
on the 2-position of the ring, allowing for differential testing for the production of 
nitroreductases by the Gram-negative bacteria.52 However, slight diffusion of 
fluorescence into media was noted with benzothiazole derivatives, similar to that of 4-
MU and 7-AMC, making them less ideal substrates.52 
 
 
Scheme 1.5 Formation and extended resonance of benzothiazole derivatives from 
fluorogenic substrates. 
 
β-Naphthylamine is a fluorogen which was originally used for the identification of 
several group A Streptococci and Enterococci via the hydrolysis of L-pyrrolidonyl-β-
naphthylamide by pyroglutamyl aminoopeptidase, Scheme 1.6.53 It is generally 
characterized by faint fluorescence, with an emission wavelength of 520 nm.54 While 
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effective in the identification of these bacteria, it should be noted that assays 
containing derivatives of 7-AMC were found to be more sensitive and easier to 
perform leading to low usage of β-naphthylamine derivatives.55 
 
Scheme 1.6 Formation and extended resonance of β-naphthylamine derivatives 
from fluorogenic substrates. 
 
 
 
To further enhance fluorescence-based detection methods, secondary reaction-based 
substrates have also been used to detect enzymatic activity. In these reactions, the 
product of the enzymatic process reacts in situ with a secondary reagent incorporated 
into the detection media to form a more favourable chromogen or fluorogen. An 
example of secondary reaction based detection is the metabolism of tryptophan to 
indole, which may be detected by its reaction with various aldehydes, such as 4-
dimethylaminobenzaldehyde or 2-ethoxy-4-dimethylbenzaldehyde, Scheme 1.7, to 
give fluorescent products.56 
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Scheme 1.7 Formation of indole from tryptophan and secondary reaction to form 
purple-red fluorescent derivatives. 
 
Currently, these media are primarily used in conjunction with chromogenic media for 
the detection of pathogenic bacteria in food and water samples.  They often rely upon 
a pH change to induce fluorescence or require the facilitated adherence of the 
fluorogenic compound onto the cell wall of bacteria to localize fluorescence.26  
 
1.3.2 Molecular diagnostic techniques 
1.3.2.1 Polymerase-chain reaction 
Polymerase-chain reaction (PCR) can be utilized as a genotypic identification method 
for bacteria. During the PCR process, the bacterial DNA is denatured and the 
expression of targeted genes is induced by oligonucleotide primers and amplified by 
Thermus aquaticus (Taq) DNA polymerase. Typically, the 16S ribosomal DNA gene 
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sequence is used as a labelling target, as it is highly conserved within bacterial 
species. Testing for the correlating DNA region allows for the identification of 
bacteria based upon their species and genotypic traits.57,58  
PCR also allows for direct testing for antimicrobial resistance by targeting the known 
resistance genes, such as the mecA gene (methicillin resistance), aacA-aphD gene 
(aminoglycoside resistance), vanA gene (vancomycin resistance), tetK and tetM genes 
(tetracycline resistance), ermA and ermC genes (macrolide-lincosamide-streptogramin 
B resistance), and the vatA, vatB, and vatC (streptogramin A resistance) genes.59 The 
high specificity of PCR for particular gene sequences also allows for the testing of 
single nucleotide polymorphisms (SNPs), such as the detection of a G2576U rRNA 
mutation which conveys linezolid resistance in colonies of Enterococcus faecalis and 
Enterococcus faecium.41,60 These amplified DNA fragments can then be used to 
identify bacteria using various detection methods. The traditional method involves the 
analysis of the DNA fragments via electrophoresis on an ethidium bromide-containing 
agarose gel along with reference markers to identify the bacterial species involved.57  
Real-time PCR utilizes fluorescent probes to increase the sensitivity and throughput 
of the assays.57,58 This increased sensitivity allows for improved identification of the 
bacteria during the exponential phase of growth greatly decreasing the time required 
for bacterial identification with results typically obtained within 1.5 hours from the 
collection of sample from the patient.  
The main advantage of PCR techniques is that only a small amount of the original 
bacterial DNA is required, which is then amplified, by-passing the need for a 
conventional enrichment culture. However, this also greatly increases the risk of false-
positive and false-negative results, and great care must be taken to avoid 
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contamination.57 Purification of clinical samples prior to PCR is necessary, as certain 
samples may contain polymerase inhibitors, hindering detection. For example, 
cerebrospinal fluid often contains hemin which inhibits Taq polymerase and may not 
be removed via conventional sample preparation.57 
While PCR is a highly advantageous method for the detection of bacteria, it  generally 
requires a high degree of training and expensive, specialized equipment to be 
implemented.58,61 As such, it is unlikely to be used in areas with low financial 
resources and untrained personnel.  
 
1.3.2.2 Fluorescent in situ hybridization 
Similarly to PCR, fluorescent in situ hybridization (FISH) can detect the presence of 
bacteria by directly detecting their 16S ribosomal RNA. In FISH, bacterial samples 
are fixed and treated with fluorescently labeled probes complementary to the 16S 
rRNA. This sample is then washed two to three times, to remove unattached labels, 
and visualized using fluorescent or laser scanning microscopy in order to identify 
bacterial species present.58 
FISH shows great promise due to its rapidity and cost-effectiveness, as well as the 
ability to test for individual resistance markers, and is currently suggested as a 
bridging technique towards PCR. While this method is highly sensitive, specific, and 
faster than normal microscopy, its reliability is highly dependent on the skills of the 
microbiologist performing the test. If the sample is not fixed and / or washed properly, 
FISH will not provide reliable results. Moreover,  natural fluorescence from the 
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investigated bacteria (and photo-bleaching) can interfere with the accuracy of results, 
as discussed above.58 
 
1.3.2.3 Matrix-assisted laser desorption / ionization-time of flight mass 
spectroscopy 
Matrix-assisted laser desorption / ionization-time of flight mass spectroscopy 
(MALDI-TOF MS) is another increasingly used technique for the detection of 
pathogenic bacteria. As with the two previously discussed methods, MALDI TOF-MS 
relies upon the conservation of the 16S rRNA segment as a means of differentiation 
between bacterial species.  
In MALDI-TOF MS, a bacterial sample (intact or extracted) is spotted onto a sample 
plate covered/fused with a chromogenic matrix. The sample plate is irradiated by a 
laser source at the wavelength at which the chromogen absorbs; this causes a rapid 
rise in temperature and leads to the vaporization of the molecules in the bacterial 
sample. The molecules in the gas phase undergo ionization, and are then repelled into 
a flight tube to determine their mass / charge ratio (m/z) by measurement of the time 
they take to reach the detector. As all the ions are given the same amount of kinetic 
energy by the repeller plate, the heavier the ions, the more slowly they travel down the 
fight tube to the detector. The distribution pattern / prevalence of the mass peaks vary 
between bacterial species. Hence, differentiation between bacterial species based upon 
their characteristic spectral fingerprints is possible, Figure 1.8.62  
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Figure 1.8  Spectral fingerprints for whole colonies of five different bacterial 
species via MALDI-TOF MS using α-cyano-4-hydroxycinnamic acid 
(HCCA) as the matrix. Taken from Carbonnelle et al.62 
 
A major drawback of this technique is that changes in extraction method, growth 
conditions, and sample preparation alter the fingerprint, making standardization of the 
technique essential.62 For example, a study involving two identical MALDI-TOF MS 
instruments at different locations showed that significantly different spectra were 
obtained when a single isolate of MRSA was tested on both machines using the same 
protocol. Although, 60% of the peaks were found to overlap, variations in  peak 
intensities were observed between identical peaks in the spectra, Figure 1.9.63 
 28 
 
 
 Figure 1.9 Spectra demonstrating inter-laboratory reproducibility of MALDI 
TOF-MS using a single isolate of MRSA on identical machines at 
Manchester Metropolitan University (MMU) (top) and Manchester 
Public Health Laboratory (MPHL) (bottom). Taken from Walker et 
al.63 
 
Additionally, as the sensitivity of MALDI-TOF MS is relatively low, enrichment of 
the samples is still required. Once cultured, results can be obtained within 5-10 
minutes using MALDI-TOF MS, thus allowing for the extremely rapid identification 
of pathogenic bacteria. However, initial start-up costs (even after the purchase of the 
MALDI-TOF spectrometer) can be extremely high due to the requirement for up-to-
date reference databases containing spectra of all known relevant bacterial species. 
Moreover, bacterial species genotypes also tend to differ from region to region, and 
individual databases must thus be set up for each individual region. As such, this 
technique is again highly unlikely to be used in remote areas.62,64 
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1.3.3 Summary of techniques 
When comparing the techniques available for the detection of pathogenic bacteria, it 
becomes apparent that each method has its own characteristics, Table 1.3, that may 
influence the suitability of the method used. As such, care must be taken when 
choosing an appropriate method to ensure that the method chosen is ideal for the 
circumstance.  
Table 1.3 Comparison of techniques available for the detection of bloodstream 
infections. 
Technique 
Characteristic 
Broad detection 
range 
Susceptibility 
testing 
Rapid Cheap Need for highly 
trained personnel 
Blood culture   ×  × 
Chromogenic / 
fluorogenic media 
×  ×  × 
PCR ? ×  ×  
FISH ? ×    
MALDI-TOF MS  ×  ×  
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1.4 Fluorescence 
1.4.1 General principles of fluorescence 
Fluorescence refers to the emission of light from a molecule or substance that has 
absorbed a form of electromagnetic radiation. In the ground state (S0), molecules can 
absorb defined packages of energy in the form of photons, raising their outer shell 
electrons into a higher energy state. When a photon is absorbed, an electron will move 
from the highest occupied molecular orbital (HOMO) to the lowest unoccupied 
molecular orbital (LUMO), to give a higher energy (excited) state (S′1). Over a short 
period of time, this excited energy state (S′1) rapidly relaxes into its lowest vibrational 
electronic excited state (S1), from which energy may be released to facilitate a return 
(relaxation) to the ground state (S0).
65 This relaxation energy may be released in 
numerous ways;  (i) dissipation by heat or vibrations into the surroundings, (ii) 
interactions with other molecules, or (iii) the emission of photons, which is referred to 
as luminescence  (phosphorescence and / or fluorescence).66 
Phosphorescence occurs when an electron is excited past a singlet state into a triplet 
state (T1) and relaxes to release energy, and is characterized by longer emission rates 
and lifetimes than fluorescence. Compounds that phosphoresce generally have 
lifetimes of milliseconds to seconds compared to the typical fluorescence lifetime of 
approximately 10 ns. Due to this enhanced half-life, phosphorescence is rarely seen in 
liquid solutions, such as media, as the excited molecule will more likely relax via 
alternate pathways which compete with emission.66 
Due to the most likely relaxation processes, the released photon will have less energy 
than that of the absorbed photon, thus will display emission of a longer wavelength 
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than the exciting light. The possible relaxation mechanisms and potential energy 
states of a molecule are commonly depicted in a Jabłoński diagram, Figure 1.10.66 
 
 
Figure 1.10 Jabłoński diagram depicting the different electronic states of common 
molecules and the transitions between energy states. Taken from Sauer 
et al.65 
 
The most common representation of fluorescence is an excitation followed by an 
emission, with the intensity of the absorbed and emitted wavelengths recorded at a 
fixed excitation and emission wavelength, respectively (Figure 1.11). The difference 
in wavelengths between excitation and emission maxima is known as the Stokes’ shift 
and is an important factor when discussing the suitability of fluorogenic compounds 
for detection purposes.66  
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Figure 1.11 Example of emission and excitation spectra of a compound and the 
associated Stokes’ shift.  
 
Ideally, a large Stokes’ shift is preferred (i.e. a large difference between excitation and 
emission wavelengths) as, if the Stokes’ shift is relatively low, there is likely to be an 
overlap between the excitation and emission wavelength ranges of the molecule, 
resulting in  a reduced effectiveness of the fluorogen, as the emission intensity will be 
reduced. 
The excitation and emission spectra of fluorescent compounds are usually almost 
symmetrical or mirror images of each other due to the similar intra-molecular energy 
transitions involved in both the absorption and emission processes in a molecule. This 
is due to the Franck-Condon principle, which describes the likelihood of electronic 
transitions within the nucleus.65 
The amount of radiation or energy absorbed by a molecule is well known and can be 
quantified employing the Beer-Lambert law; 
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𝑨 = 𝒍𝒏
𝑰𝟎
𝑰
= 𝜺𝒄𝒅 
where I0 is the background radiation emitted by the sample (in a.u.), I is the intensity 
of incident light (in arbitrary units), ε is the molar extinction coefficient (in M-1cm-1), 
c is the concentration of sample (in M), and d is the cell path length (in cm) or 
distance from incident light. The molar extinction coefficient (ε) of a molecule is 
representative of how strongly a molecule absorbs radiation at a specific wavelength, 
and can be described as the probability associated with a molecule absorbing a photon 
of a certain energy value. Similarly, the probability associated with a molecule 
emitting a photon after the absorption of energy is known as the quantum yield (Φ)  
it can be derived as a ratio of emitted and absorbed photons and is commonly used as 
a measure of emission efficiency. Consequently, a good fluorescent molecule should 
have high ε and Φ values to have high excitation and emission intensities.66 
 
1.4.2 Solvent and environmental effects upon fluorescence 
When considering fluorescence, the effect of solvents must also be taken into account. 
As mentioned previously, molecules relax from their excited energy states to the 
lower ones in various ways, which may include dissipation of heat or the transfer of 
vibrational energy into the surroundings. Collisions and interactions between 
fluorophores and surrounding molecules often provide a pathway for energy to be 
transferred, and can result in the reduction of fluorescence intensities. This pathway is 
known as solvent relaxation, when the surrounding molecules are solvent molecules, 
and can be an important factor when considering fluorescent properties. The influence 
of solvent on the relaxation can be associated to its polarity; when polar fluorophores 
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become excited, they acquire a dipole moment around which polar solvents can 
orientate. As such, more polar solvents tend to be more prone to orientation around 
fluorophores than non-polar solvents, resulting in  increased solvent relaxation 
effects.66 
 
1.5 1,8-Naphthalimide dyes 
1,8-Naphthalimide, Figure 1.12, and its derivatives are a class 
of fluorescent dyes that have been well defined and studied for 
a wide range of uses. 1,8-Naphthalimide dyes have a strong 
yellow-green fluorescence and good photo-stability due to their 
conjugated ring structure,67 with absorbance and emission 
generally occurring in the 450-330 nm and 560-370 nm 
regions, respectively.68  
 
1.5.1 Theoretical properties of 1,8-naphthalimide derivatives 
To further study the fluorescent attributes of the conjugated ring system, time-
dependent density functional theory (TDDFT) has been developed and used for the in 
silico calculation and extrapolation of the HOMO and LUMO energy states of these 
molecules, Figure 1.13.68  
 
Figure 1.12 Numbered 
chemical structure of 1,8-
naphthalimide. 
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HOMO   LUMO 
Figure 1.13  TDDFT computational presentation of HOMO and LUMO 
characteristics of 1,8-naphthalimide in a simulated ethanolic 
environment. Taken from Jacquemin et al.68 
 
 
These computational studies showed that the C-4 orbitals make a large contribution to 
both the HOMO and LUMO states, meaning that substituents at this position may 
have a significant effect upon the intensity and wavelength of the fluorescence. The 
effect of this contribution can also be enhanced through the extension of conjugation. 
An example is the use of arylhydrazone substituents in the 4-position; this results in 
changes of the corresponding calculated HOMO and LUMO states, Figure 1.14, 
which correlate to an expected increase in conjugation and hence fluorescence.69  
 
HOMO   LUMO               
Figure 1.14 TDDFT computational presentation of HOMO and LUMO 
characteristics and structure of an arylhydrazone derivative of 1,8-
naphthalimide in a simulated acetonitrile environment. Taken from 
Cheshmedzhieva et al.69 
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As seen in both computations above, the imide moiety only play a marginal role in the 
emission spectra, with little to no effect on overall fluorescence. Therefore, it is only 
expected to have a slight contribution to the HOMO and LUMO states. Consequently, 
changes to the imide moiety are not expected to significantly affect the fluorescence 
of the 1,8-naphthalimide framework. However, derivatization on the imide 
functionality can be used to alter the cell permeability and cell retention of 1,8-
naphthalimide derivatives without altering the fluorescent properties.  
 
1.5.2 Experimental investigations of properties of 1,8 naphthalimide derivatives 
The effects of various substituents at the 4-position of the naphthalimide ring have 
been studied experimentally,  demonstrating that electron-donating substituents shift 
both the absorption and emission spectra to longer wavelengths (bathochromic 
shift).70,71 The effect and intensity of this shift appears to have a largely linear 
correlation to the Hammett σ constants of the substituents investigated.72 
The majority of derivatives studied utilized an amino group in the 4-position for 
optimal fluorescence, due to its efficient electron-donating properties. If a 
dialkylamino group was substituted instead, there was a subsequent decrease in 
fluorescence yield, which was thought to be due to rotation around the 4-position 
bond causing a twisted intramolecular charge transfer state to occur. Likewise, 
substitution at the 4- position with a hydrazide group was also associated with a five-
fold decrease in quantum yield, and hence intensity, compared to an amino group.71 
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When a series of long carbon chains were attached to the 4- and imide positions of the 
1,8-naphthalimide ring, there was found to be little difference in the recorded 
fluorescence spectra and quantum yield.71 
The effects of extending conjugation have also been tested experimentally. Extension 
of the conjugated π system by the addition of aromatic rings at the 9-position had 
little-to-no effect on the fluorescence,71 although the addition of aromatic rings onto 
the 4-position did increase the fluorescence observed.72 
Experimental data also showed that if the position of substitution is changed from the 
4- to the 2- or 3-positions, the fluorescence spectrum shifts hypsochromically and 
decreases in intensity.71 Therefore, substitutions at the 4-position are optimal for 
influencing fluorescence. Di-substitution of the naphthalimide ring, in the 4- and 5-
positions, was also shown to be of little benefit to the fluorescence yield of these 
derivatives, with large steric interactions between the substituents causing them to 
orientate out of the plane of the ring.71 Use of substituted naphthalic anhydrides rather 
than substituted naphthalimides also lead to much poorer fluorescent properties, with 
a decrease in fluorescence yield.71 
 
1.5.3 Uses of 1,8-naphthalimide derivatives 
1,8-Naphthalimide and its derivatives have traditionally been used in the colouration 
of polymers,73,74 the preparation of electroluminescent materials,75 liquid crystal 
displays,76 models for photoinduced electron transfer,77,78 drug delivery systems,79–81 
and as fluorescent sensors and markers for transition metals,82–84 anions,85,86 
cations,67,87,88 carbohydrates,89 proteins,90,91 and hypoxic cells.92,93 
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For example, Ivanov et al. recently coupled 4-hydrazino-N-hexyl-1,8-naphthalimide 
to Gly-Pro, Gly-Pro-Met, and Ala-Ala-Phe for use as a differential marker for the 
enzymes dipeptidyl peptidase IV (DPP IV) and tripeptidyl peptidase I (TPP I).72 After 
enzymatic cleavage, secondary coupling of the hydrazine to aromatic aldehydes was 
also used in order to obtain a fluorescent, insoluble hydrazone with a more favourable 
emission wavelength.72 
  
Scheme 1.8 Hydrolysis of N-hexyl-1,8-naphthalimide derived substrates to form a 
fluorophore, and its subsequent reaction with piperonal. 
 
Using piperonal, Scheme 1.8, the resulting hydrazone was found to fluoresce around 
~580 nm in DMSO, Figure 1.15. Upon histochemical testing of the synthesized 
compounds on rat and mouse tissue, the substrate was seen to be cleaved and then 
react with piperonal in the vicinity of characteristic DPP IV and TPP I enzyme sites to 
display fluorescence. This result was verified with inhibition studies using irreversible 
DPP IV and TPP I inhibitors.72 
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Figure 1.15 Fluorescence emission spectrum of corresponding hydrazone from the 
reaction of N-hexyl-1,8-naphthalimide with piperonal in DMSO (λex = 
460 nm). Taken from Ivanov et al.72 
Building upon this work, Ivanov et al. then attempted to test a variety of aromatic 
aldehydes to assess the effects of an electron-donating and electron-withdrawing 
groups, Scheme 1.9.94 As expected, they reported an increase in the fluorescence 
emission maxima as the electron-donating effect of the para-substituent increased, 
Figure 1.16.94 
 
Scheme 1.9 Reaction of N-hexyl-4-hydrazino-1,8-naphthalimde derivatives with 
substituted aromatic aldehyde to form a more strongly fluorescent 
hydrazone.  
a  X = N(CH3)2, Y = H 
b X = OCH3, Y = H 
c  X = CH3, Y = H 
d X = Y = H 
e X = Cl, Y = H 
f X = CN, Y = H 
g X = NO2, Y = H 
h X = Y = OCH3 
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Figure 1.16 Normalized emission spectra of synthesized hydrazones in solid-state 
crystals (λex = 390 nm). Taken from Ivanov et al.94 
While these results are promising, these workers only reported normalized emission 
data and did not take into consideration the differences in fluorescence intensity due 
to changes in electronic properties.94 Changes in fluorescence intensity must also be 
considered when assessing the usefulness of such substrates in media. Furthermore, 
the crystal (solid-state) form of the hydrazones was used to assess fluorescence, which 
does not take into consideration environmental and solvation effects (as discussed 
previously). For use in media, and for the detection of bacteria, the analogues will be 
dissolved in a largely aqueous medium which will affect the emission maxima and 
intensity. 
Nitro group substituted 1,8-naphthalimide derivatives have also been used as a means 
of testing for cell hypoxia.92,93 Addition of a nitro substituent into the naphthalimide 
ring often quenches the fluorescence of the ring or causes a blue-shift of the emission 
maximum. However, when a cell undergoes hypoxia, the nitro groups are often bio-
reduced to amines via the expression of nitroreductases. This reduction causes an 
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increase in fluorescence observed and is thus often associated with a subsequent red-
shift in the emission maximum, Scheme 1.10. 
Scheme 1.10 Proposed detection mechanism for nitroreductase activity using a 1,8-
naphthalimide derivate.93 R = (CH2)2O(CH2)2O(C=O)CH3. 
 
A recent study by Cui et al.93 used a range of nitro-substituted 1,8-naphthalimide 
derivatives in an enzymatic study to test the effect of oxygen-sensitive nitroreductase 
expressed by E. coli. These workers found a time-dependent increase in both 
fluorescence intensity and wavelength upon exposure of the substrate to the 
nitroreductase, allowing for a ratiometric calculation of substrate to fluorophore at any 
given time by assessing the fluorescence intensity.93 
More relevant, however, is a recent patent by Anthony et al.,95 who synthesized a 1,8-
naphthalimide derivative, Figure 1.17, to test for the presence of Mycobacterium 
tuberculosis via the targeting of nitrate reductase expressed by the Mycobacteria. In 
the patent, 4-nitro-1,8-naphthalimide was used as the target with a long aliphatic N-
substituent to anchor the molecule to the surface of the agar plate.95 This long chain 
was introduced to allow for the luminescence to be visible from outside of the 
bacterial colony and reduce the potential risk to laboratory workers.  
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Figure 1.17 Structure of patented 1,8-naphthalimide derivative used in the detection 
of Mycobacterium tuberculosis.95 
 
Similar to the derivatives used for the testing of cell hypoxia, the nitro group 
quenches the fluorescence of the compound and is cleaved off in the presence of 
nitrate reductase expressed by Mycobacterium tuberculosis. The cleavage of the nitro 
group causes an increase in fluorescence intensity to occur, allowing for rapid 
detection of the Mycobacteria in media. 
 
1.6 Aims and Objectives 
The aims of this project were to synthesize novel fluorogenic substrates based on the 
1,8-naphthalimide core for the detection of bacteria in clinical samples. As a proof-of-
concept, Pseudomonas aeruginosa was chosen as the target bacterium. As this 
microorganism is known to express β-alanyl aminopeptidase, β-alanine was used as 
the targeting substrate and coupled onto 4-hydrazino-1,8-naphthalimides. In the 
presence of β-alanyl aminopeptidase, the amide bond would be hydrolyzed releasing 
β-alanine and 4-hydrazino-1,8-naphthalimide, which would undergo reaction with a 
secondary aldehyde present in the medium to generate fluorescence. If β-alanyl 
aminopeptidase was not present, then the amide bond would remain intact and 
fluorescence would not be observed. 
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The first aim was to create a number of 4-hydrazino-1,8-naphthalimide derivatives 3 
with differing N-substituents in order to evaluate the effects of chain length on the 
adherence to cells. These derivatives 3 would then be coupled to β-alanine as a 
selective fluorescent substrate 5 for β-alanyl aminopeptidase activity. The coupled 
derivatives 5 could then be incorporated into media (in the form of a salt to improve 
solubility) for the evaluation of their potential in the detection of Pseudomonas 
aeruginosa. 
 
Scheme 1.11 General scheme for the synthesis of β-alanine coupled 1,8-
naphthalimide derivatives. 
The second aim was to react the synthesized 4-hydrazino-1,8-naphthalimide 
derivatives 3 with various arylaldehydes to form hydrazones 6-10 for assessment of 
their effects on the fluorescence.  
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Scheme 1.12 General scheme for the synthesis of 1,8-naphthalimide hydrazones.
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Chapter 2 
SYNTHESIS OF 1,8-
NAPHTHALIMIDE 
DERIVATIVES
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2.1 Chemistry 
The synthesis of the designed 1,8-naphthalimide substrates was achieved in four 
steps. Firstly, a variety of 1,8-naphthalimides 2a-c were prepared from 4-bromo-1,8-
naphthalic anhydride 1 by substitution with various amines. Subsequent substitution 
of the 4-bromo group by hydrazine was then followed by amide bond formation 
between the fluorophores 3a-c and the suitably protected targeting moiety, Boc-β-
alanine. Finally, the protecting group was removed to give the final substrates 5a-c.  
All reaction products discussed in this project were analyzed after isolation using 
elemental analysis, MS (low and high resolution), IR, 1H-NMR, 13C-NMR, H-H 
COSY, DEPT-135, HMQC and/or HMBC, as appropriate. Full details of each 
compound characterized, including their spectroscopic assignments, are given within 
the experimental section. 
 
2.1.1 Synthesis of 1,8-naphthalimides derivatives 
Using a method adapted from Wang et al.,96  4-bromo-1,8-napthalic anhydride 1 was 
reacted with propylamine, pentylamine, and benzylamine, respectively, to give 2a-c, 
Scheme 2.1. High yields of each product 2a-c were obtained after recrystallization in 
ethanol. 
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Scheme 2.1  Reaction of 4-bromo-1,8-napthalic anhydride 1 with various amines to 
form 6-bromobenz[de]isoquinoline-1,3-diones 2a-c. Reagents and 
conditions: (i) RNH2, EtOH, reflux, 20-25 h. 
 
The formation of products 2a-c was confirmed by spectroscopic analysis. Reaction of 
1 with the variety of amines chosen to form 2a-c resulted in, for example, newly 
introduced proton signals in the aliphatic / aromatic region of the 1H NMR spectrum, 
corresponding to the groups in the starting amines, Table 2.1. 
 
Table 2.1  Assigned 1H NMR signals for 6-bromo-benz[de]isoquinoline-1,3-
diones 2a-c 
 Chemical Shift (ppm) 
2a 
R = (CH2)2CH3 
3.97 (2H, t, J = 7.6 Hz, NCH2), 1.64 (2H, sextet, J = 7.6 Hz, 
NCH2CH2CH3), 0.92 (3H, t, J = 7.6 Hz, NCH2CH2CH3) 
2b 
R = (CH2)4CH3 
4.02 (2H, t, J = 7.6 Hz, NCH2), 1.63 (2H, quin., J = 7.6 Hz, 
NCH2CH2CH2), 1.34-1.31 (4H, m, NCH2 CH2 CH2CH2CH3), 
0.88 (3H, t, J = 7.2 Hz, CH2CH3) 
2c 
R = CH2C6H5 
7.37 (2H, d, J = 7.4 Hz, H-2′, H-6′), 7.30 (2H, t, J = 7.4 Hz, H-
3′, H-5′), 7.24 (1H, t, J = 7.0 Hz, H-4′), 5.24 (2H, s, CH2) 
 
 
 
 
 2a 2b 2c 
R (CH2)2CH3 (CH2)4CH3 CH2C6H5 
Yield 
% 
83 62 93 
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2.1.2 Introduction of hydrazinyl group onto the 1,8-naphthalimide ring  
The 6-bromobenz[de]isoquinoline-1,3-diones 2a-c were then reacted with excess 
hydrazine hydrate under reflux in 2-butanol to form 6-hydrazinobenz[de]isoquinoline-
1,3-diones 3a-c via nucleophilic aromatic substitution,72 Scheme 2.2, which is 
facilitated by the electron withdrawing and mesomeric (-M) effects of the para-
carbonyl group. Optimization of this reaction was achieved by the addition of the 
hydrazine in two portions over a period of time, resulting in an approximate 20% 
increase in reaction yield from ~70% to ~90%. Initial attempts to isolate the product, 
involving the use of flash chromatography, were unsuccessful as the product appeared 
to degrade on 40-63 Å amorphous silica, presumably due to the relatively low pH of 
the silica. As an alternative, the product was isolated by filtration and purified by 
recrystallization of the crude residue from 2-butanol. 
 
Scheme 2.2  Substitution of bromine with hydrazine to form arylhydrazines 3a-c 
and corresponding yields. Reagents and conditions: (i) NH2NH2.H2O, 
2-BuOH, reflux, 24 h.  
 
The structure of the hydrazine derivatives was then confirmed using spectroscopic 
analysis; broad peaks for the NH and NH2 protons in DMSO-d6 were observed in the 
9.12-9.13 ppm and 4.67-4.69 ppm regions, respectively, with an upfield shift of the 
signal for H-5 due to the relative shielding effect arising from the removal of the 
 3a 3b 3c 
R (CH2)2CH3 (CH2)4CH3 CH2C6H5 
Yield 
% 
81 92 89 
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bulky bromo substituent by an electron donating (+M) hydrazino group, Table 2.2. A 
similar shift towards upfield, however, was not seen on the proton signal displayed by 
H-7, presumably due to the NH2 providing shielding for the H-7. The IR spectra of 
the hydrazines showed the addition of two broad signals, in the range of 3245-3375 
cm-1, for 3a-c as expected for the N-H vibrations. 
Table 2.2 Comparison of selected 1H NMR signals between 2a-c and 3a-c in 
DMSO-d6. 
 2a 3a 2b 3b 2c 3c 
H-5 8.15 7.24 8.23 7.24 8.22 ~7.27 
NH2 - 4.67 - 4.67 - 4.69 
NH - 9.12 - 9.12 - 9.13 
 
 
 
Figure 2.1 Aromatic regions of the 1H NMR spectra of 2a and 3a in DMSO-d6, 
showing shielding of H-5 after nucleophilic substitution of the bromo 
group by a hydrazino group. 
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2.1.3 Formation of an amide bond between 6-hydrazinobenz[de]isoquinoline-
1,3-diones 3a-c and Boc-β-Ala-OH 
 
To form the amide bond between the fluorophore hydrazine derivatives 3a-c and the 
chosen amino acid, activation of the carboxylic acid group of the N-protected amino 
acid was initially carried out to compensate for low reactivity of the carboxylic acid 
and increase the leaving group’s ability, Scheme 2.3. 
 
 
Scheme 2.3 General scheme for the activation of a carboxylic acid group and 
subsequent formation of amide bond. 
 
Initially, the method published by Ivanov et al.72 for the coupling of similar 
hydrazinoisoquinolones was followed, using  Boc-β-Ala-OH as amino acid and a 
uronium salt, O-(benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium tetrafluoroborate 
(TBTU), as the coupling / activating agent, Table 2.3, Figure 2.2. However, this 
method did not give satisfactory results and we were unable to confirm product 
formation via thin layer chromatography (TLC).  
Various other peptide coupling methods were, therefore, trialed for the optimization of 
this step, including carbodiimides, acylimidazoles, and mixed anyhydrides (Table 
2.3). In the majority of these reactions, the desired coupled product did not form 
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(when monitored by TLC) and / or a major product could not be isolated. The desired 
product was eventually obtained using pentafluorophenol (PFP) as the coupling agent, 
presumably due to the enhanced leaving group properties of the pentafluorophenolate, 
however this reaction provided very low yields (2-12%) of the products. Based upon 
the moderate success when using the PFP method, isobutyl chloroformate was then 
used, giving moderate yields (6-21%) of the desired products. 
 
Table 2.3 Coupling reagents used for amide bond formation 
 Coupling Reagent Base 
i TBTU, HOBt DIPEA 
ii EDC, HOBt Et3N 
iii CDI  
iv PFP, DCC  
v Z-Ala-OSu Et3N, DBU 
vi Isobutyl chloroformate NMM 
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Figure 2.2 Chemical structures of amide bond coupling reagents and bases in 
Table 2.3 
 
Building upon these observations, a symmetrical anhydride of Boc-β-Ala-OH was 
synthesized for use as a coupling agent via formation of an O-acylisourea using DCC. 
The by-product dicyclohexylurea, insoluble in the reaction solvent dichloromethane, 
could be readily separated by filtration and the filtrate of the desired symmetrical 
anhydride was added to a solution of 3a-c, 4-dimethylaminopyridine (DMAP) and N-
diisopropylethylamine (DIPEA) in DCM, Scheme 2.4. 
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Scheme 2.4  Yields from the coupling between 6-hydrazinobenz[de]isoquinoline-
1,3-diones 3a-c and Boc-β-alanine using the symmetrical anhydride 
method to form 4a-c. Reagents and conditions: (i) DIPEA, DMAP, 
DCM, 0 °C to rt, 24 h 
 
Isolation of the products 4a-c was achieved by flash chromatography using an 
acetone-hexane gradient, followed by further purification via recrystallization from 
ethyl acetate. Spectroscopic analysis revealed the additional signals in the 1H NMR at 
approx. δ3.4 and 2.6 ppm corresponding to the methylene moieties of β-alanine, and a 
sharp singlet (integrating for 9H) at approximately δ1.5 ppm corresponding to the 
methyl groups of the Boc-protecting group. A similar signal was also found in the 13C 
NMR at approximately δ2.97 ppm corresponding to the Boc-protecting group. The 
 4a 4b 4c 
R (CH2)2CH3 (CH2)4CH3 CH2C6H5 
Yield 
% 
21 19 34 
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mass spectra showed a corresponding increase in mass of ~171 compared to starting 
material in line with expected results. 
2.1.4 Removal of the Boc protecting group 
The Boc-protecting group was initially removed from 4a-c using hydrobromic acid, 
similar to the method used by Ivanov et al.72 However, the isolated bromide salts 
displayed no fluorescence, presumably due to the electron-withdrawing properties of 
the bromide ion quenching fluorescence.97 Trifluoroacetic acid (TFA) in 
dichloromethane (DCM) was, therefore, used as an alternative to form a 
trifluoroacetate salt (5a-c) which still retained fluorescence, Scheme 2.5. Formation of 
salts, instead of neutral free amines was preferred in order to benefit from their water 
solubility and enable their evaluation in vivo, in aqueous-based growth media. 
 
 
 
 
 
Scheme 2.5 Deprotection of 4a-c to form fluorogenic trifluoroacetate salts 5a-c. 
Reagents and conditions: (i) TFA/DCM (1:6 v:v), 0 °C to rt, 2 h 
 
Confirmation of the isolation of the desired product was achieved by spectroscopic 
analysis, in particular the disappearance of the characteristic Boc singlet at 
approximately δ1.5 ppm in the 1H NMR spectra. The formation of the final products 
was also confirmed by high-resolution mass spectroscopy. Purity, however, could not 
be confirmed via elemental analysis for these products. 
 5a 5b 5c 
R (CH2)2CH3 (CH2)4CH3 CH2C6H5 
Yield 
% 
89 94 96 
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2.1.5 Condensation reaction of hydrazines 3a-c with benzaldehydes 
In order to form the hydrazones 6-10, which are expected to display increased 
fluorescence intensities due to their extended conjugation, a number of variously 
substituted benzaldehydes were reacted with the hydrazines 3a-c via a nucleophilic 
condensation reaction. A range of benzaldehydes such as benzaldehyde, 4-
chlorobenzaldehyde, 4-methoxybenzaldehyde, 4-dimethylaminobenzaldehyde, and 
cinnamaldehyde were chosen in order to assess the effects of the different electronic 
configurations upon the observed fluorescence.  
The aldehyde and the appropriate hydrazine 3a-c were stirred under reflux in ethanol 
for two hours, in the presence of catalytic amounts of glacial acetic acid, Scheme 2.6. 
The products, as a range of orange to dark purple solids, were isolated by the filtration 
of the precipitate formed upon cooling without further purification, Table 2.4. 
. 
Scheme 2.6 Reaction of substituted benzaldehydes and cinnamaldehyde with 
hydrazines 3a-c to form fluorescent hydrazones 6-10. Reagents and 
conditions: (i) EtOH, reflux, 2 h 
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Table 2.4  Yields (%) obtained from the synthesis of hydrazones 6-10 
 6 7  8 9  10 
a 
R = (CH2)2CH3 
76 77 92 80 76 
b 
R = (CH2)4CH3 
34 91 48 21 82 
c 
R=CH2C6H5 
55 66 76 72 58 
 
The formation of the desired structures was confirmed by spectroscopic analysis by 
identifying, for example, the additional characteristic proton signals corresponding to 
the imine (N=CH) moiety, typically around δ8.4 ppm, as well as those associated with 
the aromatic ring, Table 2.5. Elemental analyses were also undertaken on all products 
to confirm formation and purity of desired product.  
Table 2.5 Assigned 1H NMR imine (N=CH) signals for 6-10a and 6-10b in 
acetone-d6, and 6-10c in DMSO-d6 
 δH  δH  δH  δH  δH 
6a 8.39 7a 8.38 8a 8.34 9a 8.28 10a 8.23 
6b 8.39 7b 8.34 8b 8.34 9b 8.33 10b 8.22 
6c 8.47 7c 8.44 8c 8.42 9c ~8.38 10c 8.31 
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Chapter 3 
EVALUATION OF 
FLUORESCENT PROPERTIES
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3.1 Fluorescence of synthesized derivatives 
As discussed earlier, for suitable use as an indicator for pathogenic bacteria, 
fluorogens 5a-c must exhibit either a significant change in fluorescence intensity or a 
significant shift in the emission wavelength when compared to that of the 
fluorophores 3a-c.  
In order to evaluate the fluorescence properties of all synthesized hydrazines 3a-c, 
Boc-protected hydrazines 4a-c, intended enzyme substrates 5a-c, and hydrazones 6-
10, qualitative spectroscopic analysis was performed at a concentration of 1× 10-4 M 
in ethanol. The hydrazones 6a-c and 7a-c displayed significantly increased 
fluorescence surpassing the detection limit of the Shimadzu RF-5301PC 
spectrophotometer and a lower concentration of 1 × 10-5 M in ethanol was used for 
final qualitative comparison. 
Differences in the N-substituents on the 1,8-naphthalimide moiety displayed relatively 
little effect on the fluorescence properties observed (Figures 3.1 and 3.2 and Table 
3.1) with the exception of 3c, where markedly increased fluorescence intensity was 
observed compared to derivatives 3a-b, as shown in Figure 3.1. Interestingly, this 
increase in fluorescence disappeared once 3c was coupled to Boc-β-alanine (4,5) or 
when reacted with an aldehyde to form hydrazones 6-10. This decrease in intensity is 
presumably due, in part, to the engagement of the lone pair of the 4-hydrazinyl moiety 
in further resonance structures of 4-10. 
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Figure 3.1 Fluorescence emission spectra of 3a (dark blue), 3b (medium blue), 3c 
(light blue), 4a (dark red), 4b (medium red), 4c (light red), 5a (dark 
green), 5b (medium green), and 5c (light green) (1 × 10-4 M in EtOH) 
(intensities are shown in arbitrary units) 
 
Table 3.1 Excitation wavelengths (λex), emission wavelengths (λem) and the 
corresponding Stokes’ shifts (Δν) of 3a-c, 4a-c, and 5a-c in ethanol 
Compound λex (nm) λem (nm) Δν (nm) 
3 
a 465 535 70 
b 476 534 58 
c 472 536 64 
4 
a 449 515 66 
b 447 516 69 
c 446 517 71 
5 
a 443 510 67 
b 444 511 67 
c 442 509 67 
 
 
Coupling of 3a-c to Boc-β-alanine to give the protected derivatives 4a-c produced a 
hypsochromic effect with an average shift of the emission maximum of 21 nm. 
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Fluorescence intensity decreased upon formation of the amides 4a-c, with a return to 
original fluorescent intensity upon removal of the Boc group 5a-c, with the exception 
of 5c. This chemical modification also resulted in a further small hypsochromic effect, 
shifting the emission wavelengths to 509-511 nm, Table 3.2. With respects to the 
Stokes’ shift, the difference between excitation and emission wavelengths remained 
relatively consistent within experimental error throughout the different chemical 
modifications of the core structure. 
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Figure 3.2 Emission spectra of hydrazones 6a (dark red line), 6b (medium red 
line), 6c (light red line), 7a (dark purple line), 7b (medium purple line), 
7c (light purple line),  8a (dark green line), 8b (medium green line), 8c 
(light green line), 9a (dark blue line), 9b (medium blue line), 9c (light 
blue line), 10a (dark orange line), 10b (medium orange line), and 10c 
(light orange line) (6-7: 1 × 10-5 M in EtOH, 8-10: 1 × 10-4 M in EtOH) 
(intensities are shown in arbitrary units) 
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Table 3.2 Excitation wavelengths (λex), emission wavelengths (λem) and the 
corresponding Stokes’ shifts (Δν) of hydrazones 6-10 in ethanol 
Compound λex (nm) λem (nm) Δν (nm) 
6 
a 467 538 71 
b 469 538 69 
c 472 538 66 
7 
a 467 536 69 
b 467 536 69 
c 471 537 66 
8 
a 517 559 42 
b 519 557 38 
c 517 559 42 
9 
a 433 587 154 
b 424 571 147 
c 433 579 146 
10 
a 516 553 37 
b 516 555 39 
c 519 554 35 
 
Formation of hydrazones with aryl aldehydes 6-10 greatly increased the relative 
intensity of the fluorescence (2-fold to > 10-fold) in most cases (except for 9a-c) and 
had a bathochromic effect (compounds 8-10) on the maximum emission wavelength 
when compared to hydrazides 3a-c. The extent of this bathochromic effect maximum 
can be related to the electron-withdrawing / donating characteristics of the aryl 
aldehydes used (4-N(CH3)2 > 4-OCH3 > benzaldehyde > 4-Cl). Electron-donating 
substituents 8-9 displayed greater bathochromic effects (Δ 20-49 nm), while electron-
withdrawing substituents 7a-c had insignificant effects on the emission wavelengths 
when compared to compounds 6a-c. Further extension of the conjugation, as seen in 
compounds 10a-c, resulted in a similar bathochromic effect to that of compounds 8a-
c, containing a weakly electron-donating group. 
Hydrazones 9a-c, containing a dimethylamino group, produced only slight 
fluorescence at the concentration studied (1 × 10-4 M) when observed with the naked 
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eye under a UV light source, as well as when measured by the 
fluorospectrophotometer. The otherwise uniform measurement parameters were 
modified for these compounds; the slit width was increased to 10 mm from 5 mm in 
order to record the maximum excitation and emission wavelengths. Gan et al.76 
observed reduction in fluorescence in a related series of compounds containing N,N-
dimethylamino substituents and suggested that this reduction in fluorescence intensity 
may be due to the facilitated rotation of the dimethylamino group, causing a 
disruption in the electronic properties, and thus quenching the fluorescence. They also 
hypothesized that hindering this rotational means of decay back to the ground state, 
while maintaining the electron-donating property of this substituent, may result in an 
increased bathochromic effect while retaining the intensity of the fluorescent 
emission. The reduced fluorescence observed with hydrazones 8a-c and 10a-c may 
also be the result of rotational decay quenching the fluorescent emission. 
The greatest intensities for the fluorescence emission were observed with the 
benzaldehyde (6a-c) and 4-chlorobenzaldehyde (7a-c) based molecules. This is 
consistent with TDDFT computations performed by Cheshmedzhieva et al.69 who 
predicted that molecules such as 7a-c would have the most efficient fluorescent 
properties based upon their electronic properties. This is thought to be due to the 
electron-withdrawing properties of chlorine in the para-position, pulling electrons 
away from the benzene ring allowing for increased resonance. 
Ideally, the observed fluorescence of the hydrazones 6-10 must significantly increase 
intensity or have a large bathochromic effect from 5a-c in order to allow for the 
colour differentiation which is essential for utilization in culture media. While 
hydrazones 7a-c show great promise in terms of fluorescence intensity, the lack of a 
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major bathochromic shift from 5a-c limits their usefulness, as changes in fluorescence 
intensity may be difficult to discern. On the contrary, hydrazones 9a-c display 
significant bathochromic shifts in comparison to 3a-c and 5a-c, but this is 
accompanied by a marked quenching of fluorescence.  
 
3.2 Biological evaluation of substrates 5a-c in Columbia agar 
Based on the fluorescent properties exhibited and discussed in Section 3.1, 
preliminary biological evaluations in media were performed by incorporation of the 
substrates 5a-c into commercially available Columbia agar medium. Biological 
testing was performed by Prof. John D. Perry at the Freeman Hospital, Newcastle 
upon Tyne, UK. Data is summarized in Table 3.4. 
Substrates 5a-c (100 mg/L) were dissolved into Columbia agar using 0.5 % N-methyl-
2-pyrrolidone (NMP) as the solvent, and incubated with a range of common 
nosocomial bacteria and fungi (Table 3.3) on air-dried and autoclaved agar plates 
(Figures 3.3 and 3.4). Ten Gram negative bacteria (1-10), eight Gram positive bacteria 
(11-18), and two fungi (19-20) were chosen for inoculation onto the plate, with 
100,000 CFU per spot, and incubated at 37 °C for 18 hours. Columbia agar without 
substrate was also incubated at 37 °C for 18 hours and used as a control. 
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Table 3.3 List of microorganisms inoculated onto incubation plates and 
corresponding spots (100,000 CFU/spot) 
Spot Organism Spot   Organism 
1 Escherichia coli 11 Streptococcus pyogenes 
2 Klebsiella pneumonia 12 Staphylococcus aureus (MRSA) 
3 Providencia rettgeri 13 Staphylococcus aureus 
4 Enterobacter cloacae 14 Staphylococcus epidermidis 
5 Serratia marcescens* 15 Listeria monocytogenes 
6 Salmonella typhimurium 16 Enterococcus faecium 
7 Pseudomonas aeruginosa* 17 Enterococcus faecalis 
8 Yersinia enterocolitica 18 Bacillus subtilis 
9 Burkholderia cepacia* 19 Candida albicans 
10 Acinetobacter baumannii 20 Candida glabrata 
*β-alanyl aminopeptidase producing bacteria 
 
 
 
Figure 3.3 Schematic representation of incubation plates; numbers correspond to 
organisms listed in Table 3.3. 
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Figure 3.4 Culture of various bacterial species in Columbia agar media containing 
substrates 5a (top left), 5b (top right), 5c (bottom left), and control (bottom right); 
microorganism colonies correspond to numbered plate, Figure 3.3. 
 
Incorporation of substrates 5a-c into Columbia agar created a slightly yellow coloured 
agar. Upon inoculation, Figure 3.4, substrates 5b (R = (CH2)4CH3) and 5c (R = 
CH2C6H5), containing bulkier chain length side-chains, exhibited bactericidal activity, 
which was strongest against Gram positive and fungal species with lesser effects on 
Gram negative species. This antibacterical effect is presumed to be due to the longer 
alkyl chains causing a disruption of the cell wall membrane of the bacteria. 
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Figure 3.5 Observed fluorescence of various bacterial species in Columbia agar 
media containing substrates 5a (top left), 5b (top right), 5c (bottom 
left), and control (bottom right), λex = 365 nm); microorganism 
colonies correspond to numbered plate, Figure 3.3. 
  
While the Columbia agar displayed little background fluorescence, uptake of the 
substrates 5a-c into the bacterial cell greatly increased and localized the fluorescence, 
Figure 3.5. When comparing the excitation spectra of the substrates 5a-c to the 
fluorophores 3a-c, it becomes apparent that the observed fluorescence of the bacterial 
colonies is primarily due to the substrates and not the fluorophores, Figure 3.6. 
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Figure 3.6 Excitation spectra of substrate 5a (red line) and fluorophore 3a (blue 
line) (1x10-4 M in EtOH) (intensities are shown in arbitrary units) 
 
As the fluorescence is primarily due to the substrates and not the fluorophores, no 
differentiation was observed between β-alanyl aminopeptidase producing (spots 5, 7, 
and 9, Table 3.3) and non β-alanyl aminopeptidase producing bacteria. The high level 
of localization of the fluorescence, however, is ideal for the sensitive detection of 
bacteria. As substrate 5a appeared to show localized fluorescence for all the tested 
microorganisms, except Streptococcus pyogenes (spot 11, Figure 3.5), it may be a 
useful lead for the detection of any bacterial infection when the actual identification 
of the microorganism is of secondary importance. For example, it may easily be used 
for the detection of any bacterial presence in blood (e.g. for the diagnosis of bacterial 
infection prior to the development of sepsis). A rapid method for the detection of 
viable bacteria in blood would enable the timely administration of antibacterial 
agents, thereby decreasing the morbidity and mortality associated with sepsis and 
reducing the incidence of antibacterial administration in cases of viral disease. 
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Table 3.4 Inhibitory effects and fluorescence of substrates 5a-c on Columbia agar against a range of bacteria and fungi 
Code 
CONTROL  (Columbia agar) 5a 5b 5c 
Name 
Organism Growth Colour Fluorescence Growth Colour Fluorescence Growth Colour Fluorescence Growth Colour Fluorescence 
1  Escherichia coli  ++  - 
 
 ++  -  + yellow  -  - 
 
 -  - 
 2  Klebsiella pneumoniae  ++  - 
 
 ++  -  + yellow  -  - 
 
 -  - 
 3  Providencia rettgeri  ++  - 
 
 ++  +/- yellow  ++ yellow  +  +/- yellow  + yellow  +  +/- yellow  + yellow 
4  Enterobacter cloacae  ++  - 
 
 ++  -  + yellow  +  +/- yellow  + yellow  +  +/- yellow  + yellow 
5  Serratia marcescens  ++  - 
 
 ++  + yellow  ++ yellow  +  +/- yellow  + yellow  +  +/- yellow  + yellow 
6  Salmonella typhimurium  ++  - 
 
 ++  -  + yellow  -  - 
 
 -  - 
 7  Pseudomonas aeruginosa  ++ Tr. Green 
 
 ++  -  + yellow  -  - 
 
 -  - 
 8  Yersinia enterocolitica  ++  - 
 
 ++  -  + yellow  -  - 
 
 +  - 
 9  Burkholderia cepacia  ++  - 
 
 +  -  +/- yellow  +  -  +/- yellow  +  - 
 10  Acinetobacter baumannii  ++  - 
 
 ++  + yellow  ++ yellow  -  - 
 
 +  +/- yellow  + yellow 
11  Steptococcus pyogenes  +  - 
 
 +/-  -  -  -  - 
 
 -  - 
 12  Staphylococcus aureus (MRSA)  +  - 
 
 +  -  + yellow  -  - 
 
 -  - 
 13  Staphylococcus aureus  +  - 
 
 +  -  + yellow  -  - 
 
 -  - 
 14  Staphylococcus epidermidis  +  - 
 
 +  -  +/- yellow  -  - 
 
 -  - 
 15  Listeria monocytogenes  +  - 
 
 +  -  +/- yellow  -  - 
 
 -  - 
 16  Enterococcus faecium  +  - 
 
 +  -  +/- yellow  -  - 
 
 -  - 
 17  Enterococcus faecalis  +  - 
 
 +  -  +/- yellow  -  - 
 
 -  - 
 18  Bacillus subtilis  +  +/- orange 
 
 +  +/- orange  -  -  - 
 
 -  - 
 19  Candida albicans  +  - 
 
 +  -  -  -  - 
 
 -  - 
 20  Candida glabrata  +/-  - 
 
 -  -  -  -  - 
 
 -  - 
 
Background / comments   None     Yellow     Yellow     Yellow   
    
 
    
 
    
 
    
 
  
    
 
  Substrate at 100 mg/L Substrate at 100 mg/L Substrate at 100 mg/L 
  Inoculum: 100 000 cfu/spot Inoculum: 100 000 cfu/spot Inoculum: 100 000 cfu/spot Inoculum: 100 000 cfu/spot 
    
 
  0.5 % NMP as solvent. 0.5 % NMP as solvent. 0.5 % NMP as solvent. 
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3.3 Conclusions and future work 
A series of novel 1,8-naphthalimide fluorophores 3a-c were synthesized. These 
derivatives 3a-c were then coupled to β-alanine to form substrates 5a-c for β-alanyl 
aminopeptidase. These substrates were found to display weak fluorescence around 
510 nm in ethanol and preliminary biological data was obtained. Fluorescence 
appeared to be localized within the cell colonies with little diffusion into the 
surrounding media, making them an ideal candidate for bacterial detection. However, 
substrates 5b and 5c, were associated with bactericidal activity against all Gram-
positive and a majority of the Gram-negative bacteria and would not be suitable 
candidates for incorporation into media.  
Enhanced differentiation between substrate 5a-c and released fluorophore 3a-c by 
specific enzyme activity may be achieved via a secondary reaction with the 
incorporation of an aldehyde into the growth media. To test this theory, the 
fluorophore 3a-c was reacted with a series of para-substituted benzaldehydes and 
cinnamaldehyde to alter the fluorescence of the fluorophore. Addition of electron-
donating para-substituted benzaldehydes appeared to form a hydrazone 9a-c with the 
desired emission wavelengths, although quantum yields were severely reduced.  
When comparing the excitation spectra of the synthesized hydrazones (Figure 3.7), it 
also becomes clear that a different excitation wavelength must be used to achieve 
maximum fluorescence results. For example, hydrazones 6a-c and 7a-c would 
fluoresce greater with a λex of ~470 nm and hydrazones 8a-c and 10a-c would 
fluoresce better with a λex of ~515 nm compared to the utilized λex of 365 nm, Figure 
3.7. 
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Figure 3.7  Excitation spectra of hydrazones 6a (red line), 7a (purple line), 8a 
(green line), 9a (blue line), and 10a (orange line) (6-7: 1x10-5 M in 
EtOH, 8-10: 1x10-4 M in EtOH) (intensities are shown in arbitrary 
units) 
 
Future work should examine the effects of more strongly electron-donating 
substituents with less rotatable bonds, such as those containing a julolidine ring, 
Figure 3.8. The julolidine ring keeps the electron-donating group planar with the 
benzene ring and reduces the likelihood of the formation of twisted intramolecular 
charge transfer states, which may reduce the quantum yield. 
 
Figure 3.8 Proposed structure of hydrazone containing julolidine ring to be 
synthesized in future work 
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Chapter 4 
EXPERIMENTAL DATA
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4.1 General chemistry 
All reagents and solvents were purchased from Sigma-Aldrich and ChemSupply, 
respectively, and used without any further purification or treatment. Thin layer 
chromatography was performed on Grace Reveleris® Silica Aluminum-backed TLC 
Plates (UV254). 1H and 13C NMR spectra were acquired on a Varian Gemini 2000 
400MR at 400 MHz and 100 MHz, respectively. Coupling constants (J) are in Hertz 
(Hz), chemical shifts (δ) are expressed in parts per million (ppm) and reported relative 
to residual solvent peaks. Melting points were obtained on a Stuart Scientific SMP 10. 
Low resolution mass spectra were obtained on TSQ Quantum Access Max (Triple 
Quadrupole) LCMS/MS in positive ion mode. High resolution mass spectra were 
obtained on a Bruker 7T Fourier Transform Ion Cyclotron Resonance Mass 
Spectrometer (FTICR) in positive ion mode.  Infrared spectra were recorded on a 
Shimadzu FTIR-8400S and a Shimadzu IRTracer-100. Elemental analyses for C, H, 
and N were obtained from the Campbell Microanalytical Laboratory in the University 
of Otago, NZ.   
 
4.2 Experimental methods 
4.2.1 General method for preparation of 6-bromo-1H-benz[de]isoquinoline-
1,3(2H)-diones 2 
4-Bromo-1,8-naphthalic anhydride 1 (1 equiv.) and the corresponding amine (1 
equiv.) were refluxed in ethanol (25 mL) for 2 hours. The solution was then allowed 
to cool to room temperature and the precipitate which formed was collected by 
filtration. The product was then further purified via recrystallization in ethanol to give 
the desired product 2a-c.  
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4.2.1.12-Propyl-6-bromo-1H-benz[de]isoquinoline-1,3(2H)-dione 2a 
Following the general method, 4-bromo-1,8-naphthalic anhydride 1 (4.00 g, 14.43 
mmol) and propylamine (1.19 mL, 14.43 mmol) were reacted to give the title 
compound as a cream brown powder (3.83 g, 83%); mp 130-132 °C; 1H NMR (400 
MHz, (CD3)2SO) δH 8.50 (1H, d, J = 7.2 Hz, H-9), 8.47 (1H, d, J = 8.4 Hz, H-7), 8.26 
(1H, d, J = 8.0 Hz, H-4), 8.15 (1H, d, J = 8.0 Hz, H-5), 7.96-7.92 (1H, m, H-8), 3.965 
(2H, t, J = 7.6 Hz, H-1′), 1.64 (2H, sextet, J = 7.6 Hz, H-2′), 0.92 (3H, t, J = 7.6 Hz, 
H-3′); 13C NMR (100 MHz, (CD3)2SO) δC 162.74 (C=O, C-1), 162.69 (C=O, C-3), 
132.4 (CH, C-9), 131.4 (CH, C-7), 131.2 (CH, C-5), 130.8 (CH, C-4), 129.6 (quat., C-
6a), 129.0 (quat., C-6), 128.65 (CH, C-8), 128.1 (quat., C-3b), 122.6 (quat., C-9a), 
121.8 (quat., C-3a), 41.25 (CH2, C-1′), 20.7 (CH2, C-2′), 11.3 (CH3, C-3′); FT-IR 
(Nujol, cm-1): 1698 (C=O), 1661 (C=O), 1585 (C=C), 1568 (C=C); ESI-MS: m/z 318, 
320 (MH+) 
 
 
4.2.1.2 2-Pentyl-6-bromo-1H-benz[de]isoquinoline-1,3(2H)-dione 2b 
Following the general method, 4-bromo-1,8-naphthalic anhydride 1 (4.00 g, 14.43 
mmol) and pentylamine (1.67 mL, 14.43 mmol) were reacted to give  light brown 
needle-like crystals of the title compound (3.12 g, 62%); mp 94-96 °C; 1H NMR (400 
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MHz, (CD3)2SO) δH 8.51 (1H, dd, J = 7.6 Hz, 0.8 Hz, H-9), 8.48 (1H, dd, J = 8.4 Hz, 
0.8 Hz, H-7), 8.27 (1H, d, J = 8.0 Hz, H-4), 8.16 (1H, d, J = 8.0 Hz, H-5), 7.95 (1H, 
dd, J = 8.4 Hz, 7.6 Hz, H-8), 3.99 (2H, t, J = 7.6 Hz, H-1′), 1.62 (2H, quintet, J = 7.6 
Hz, H-2′), 1.36-1.30 (4H, m, H-3′, H-4′), 0.87 (3H, t, J = 7.6 Hz, H-5′); 13C NMR 
(100 MHz, (CD3)2SO) δC 162.74 (C=O, C-1), 162.69 (C=O, C-3), 132.5 (CH, C-9), 
131.5 (CH, C-7), 131.2 (CH, C-5), 130.9 (CH, C-4), 129.7 (quat., C-6a), 129.0 (quat., 
C-6), 128.7 (CH, C-8), 128.2 (quat., C-3b), 122.6 (quat., C-9a), 121.9 (quat., C-3a), 
39.6 (CH2, C-1′), 28.6 (CH2, C-3′), 27.0 (CH2, C-2′), 21.8 (CH2, C-4′), 13.8 (CH3, C-
5′); FT-IR (neat, cm-1): 1697 (C=O), 1647 (C=O), 1591 (C=C), 1570 (C=C), 1560 
(C=C); ESI-MS: m/z 346, 348 (MH+) 
 
 
4.2.1.3 2-Benzyl-6-bromo-1H-benz[de]isoquinoline-1,3(2H)-dione 2c 
Following the general method, 4-bromo-1,8-naphthalic anhydride 1 (3.50 g, 12.63 
mmol) and benzylamine (1.38 mL, 12.63 mmol) were reacted to give the title 
compound as a cream brown powder (4.28 g, 93 %); mp 173-174 °C; 1H NMR (400 
MHz, (CD3)2SO) δH 8.575-8.515 (2H, m, H-7, H-9), 8.33 (1H, d, J = 7.6 Hz, H-4), 
8.20 (1H, d, J = 7.6 Hz, H-5), 8.00-7.955 (1H, m, H-8), 7.37 (2H, d, J = 7.4 Hz, H-
2′,6′), 7.30 (2H, t,  J = 7.4 Hz, H-3′,5′), 7.24 (1H, t, J = 7.0 Hz, H-4′), 5.23 (2H, s, 
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CH2); 
13C NMR (100 MHz, (CD3)2SO) δC 162.91 (C=O, C-1), 162.86 (C=O, C-3), 
137.0 (quat., C-1′), 132.8 (CH, C-9), 131.8 (CH, C-7), 131.3 (CH, C-5), 131.2 (CH, 
C-4), 129.8 (quat., C-6a), 129.3 (quat., C-6), 128.8 (C-8), 128.32 (quat., C-3b), 128.29 
(2 × CH, C-3′, C-5′), 127.5 (2 × CH, C-2′, C-6′), 127.0 (CH, C-4′), 122.6 (quat., C-
9a), 121.8 (quat., C-3a), 43.0 (CH2); FT-IR (Nujol, cm
-1): 1698 (C=O), 1657 (C=O), 
1587 (C=C), 1568 (C=C), 1495 (C=C); ESI-MS: m/z 366, 368 (MH+) 
 
 
4.2.2 General method for the preparation of 6-hydrazino-1H-
benz[de]isoquinoline-1,3(2H)-diones 3 
The 2-alkyl-6-bromobenz[de]isoquinolin-1,3(2H)dione  2a-c (1 equiv.) was reacted 
with hydrazine hydrate (2 equiv.) in 2-butanol (25 mL) under reflux. After 2 hours, 
additional hydrazine hydrate (2 equiv.) was added to the solution and after an 
additional 4 hours, the solution was allowed to cool to room temperature. The 
precipitate which formed was then purified via recrystallization in 2-butanol to give 
product 3a-c. 
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4.2.2.1 2-Propyl-6-hydrazino-1H-benz[de]isoquinoline-1,3(2H)-dione 3a 
Using the general method, bromobenz[de]isoquinolin-1,3(2H)dione 2a (3.00 g, 9.42 
mmol) was reacted with hydrazine hydrate (0.93 mL, 18.85 mmol) to give the title 
compound as an orange powder (2.05 g, 81%); mp 225-230 °C; 1H NMR (400 MHz, 
(CD3)2SO) δH 9.12 (1H, broad s, NH), 8.61 (1H, d, J = 8.4 Hz, H-7), 8.41 (1H, d, J = 
7.2 Hz, H-9), 8.28 (1H, d, J = 8.8 Hz, H-4), 7.65-7.61 (1H, m, H-8), 7.24 (1H, d, J = 
8.8 Hz, H-5), 4.67 (2H, s, NH2), 3.97 (2H, t, J = 7.6 Hz, H-1′), 1.62 (2H, sextet, J = 
7.6 Hz, H-2′), 0.90 (3H, t, J = 7.6 Hz, H-3′); 13C NMR (100 MHz, (CD3)2CO) δC 
165.8 (C=O, C-1), 165.2 (C=O, C-3), 149.1 (quat., C-6), 135.2 (CH, C-4), 132.4 (CH, 
C-9), 131.45 (quat., C-3b), 129.5 (CH, C-7), 126.5 (CH, C-8), 124.7 (quat., C-9a), 
121.1 (quat., C-6a), 113.7 (quat., C-3a), 109.1 (CH, C-5), 42.9 (CH2, C-1′), 23.1 (CH2, 
C-2′), 12.7 (CH3, C-3′); FT-IR (Nujol, cm-1): 3375 (NH), 3316  (NH), 1668 (C=O), 
1635 (C=O), 1575 (C=C), 1539 (C=C); ESI-MS: m/z 270 (MH+) 
 
 
4.2.2.2 2-Pentyl-6-hydrazino-1H-benz[de]isoquinoline-1,3(2H)-dione 3b 
Using the general method, bromobenz[de]isoquinolin-1,3(2H)dione 2b (2.50 g, 7.22 
mmol) was reacted with hydrazine hydrate (0.71 mL, 14.44 mmol) to give the title 
compound as an orange powder (1.98 g, 92 %); mp 155-157 °C; 1H NMR (400 MHz, 
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(CD3)2SO) δH 9.12 (1H, broad s, NH), 8.60 (1H, d, J = 8.4 Hz, H-7), 8.41 (1H, d, J = 
7.2 Hz, H-9), 8.28 (1H, d, J = 8.8 Hz, H-4), 7.65-7.61 (1H, m, H-8), 7.24 (1H, d, J = 
8.4 Hz, H-5), 4.67 (2H, s, NH2), 3.99 (2H, t, J = 7.6 Hz, H-1′), 1.60 (2H, quintet, J = 
7.6 Hz, H-2′), 1.35-1.28 (4H, m, H-3′, H-4′), 0.87 (3H, t, J = 7.2 Hz, H-5′); 13C NMR 
(100 MHz, (CD3)2CO) δC 165.7 (C=O, C-1), 165.1 (C=O, C-3), 149.0 (quat., C-6), 
135.1 (CH, C-4), 132.3 (CH, C-9), 131.4 (quat., C-3b), 129.2 (CH, C-7), 126.4 (CH, 
C-8), 124.6 (quat., C-9a), 121.0 (quat., C-6a), 113.7 (quat., C-3a), 109.1 (CH, C-5), 
41.3 (CH2, C-1′), 31.0 (CH2, C-3′), 29.5 (CH2, C-2′), 24.1 (CH2, C-4′), 15.3 (CH3, C-
5′); FT-IR (neat, cm-1): 3283 (NH), 3265 (NH), 1695 (C=O), 1641 (C=O), 1577 
(C=C), 1541 (C=C); ESI-MS: m/z 298 (MH+) 
 
 
4.2.2.3 2-Benzyl-6-hydrazino-1H-benz[de]isoquinoline-1,3(2H)-dione 3c 
Using the general method, bromobenz[de]isoquinolin-1,3(2H)dione 2c (1.83 g, 4.96 
mmol) was reacted with hydrazine hydrate (0.49 mL, 9.92 mmol) to give the title 
compound as an orange powder (1.39 g, 89 %); mp 202-207 °C; 1H NMR (400 MHz, 
(CD3)2SO) δH 9.13 (1H, broad s, NH), 8.63 (1H, d, J = 8.4 Hz, H-7), 8.43 (1H, d, J = 
7.2 Hz, H-9), 8.30 (1H, d, J = 8.8 Hz, H-4), 7.66-7.62 (1H, m, H-8), 7.37-7.20 (6H, 
m, H-5, H-2′, H-3′, H-4′, H-5′, H-6′), 5.21 (2H, s, CH2), 4.69 (2H, s, NH2); 13C NMR 
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(100 MHz, (CD3)2CO) δC 165.9 (C=O, C-1), 165.2 (C=O, C-3), 149.3 (quat., C-6), 
140.3 (quat., C-1′), 135.5 (CH, C-4), 132.7 (CH, C-9), 131.5 (quat., C-3b), 130.1 (2 × 
CH, C-3′, C-5′), 130.0 (2 × CH, C-2′, C-6′), 129.6 (CH, C-7), 128.8 (CH, C-4′), 126.5 
(CH, C-8), 124.5 (quat., C-9a), 121.1 (quat., C-6a), 113.4 (quat., C-3a), 109.2 (CH, C-
5), 44.6 (CH2); FT-IR (Nujol, cm
-1): 3315 (NH), 3245 (NH), 1683 (C=O), 1646 
(C=O), 1576 (C=C), 1539 (C=C); ESI-MS: m/z 368 (MH+) 
 
 
4.2.3 General method for the coupling of hydrazides to Boc-β-alanine 
Boc-β-Ala-OH (4 equiv.) was dissolved in DCM (25 mL) and cooled to 0 °C. DCC (2 
equiv.) was added to this solution, which was stirred for 1 hour. The precipitate which 
formed was filtered off and the filtrate added to a solution of 
hydrazinobenz[de]isoquinolin-1,3(2H)dione 3a-c (1 equiv.), DIPEA (1 equiv.), and 
DMAP (0.5 equiv.) in DCM (20 mL). After 3 hours, additional Boc-β-Ala-OH (4 
equiv.) and DCC (2 equiv.) was stirred in DCM (25 mL) in a separate flask in an ice 
bath for 1 hour. The filtrate was again filtered off and added to the solution. After a 
further 20 hours, the solvent was removed in vacuo and residue was purified via 
column chromatography on silica gel using an acetone-hexane gradient. 
Recrystallization from ethyl acetate gave the Boc-protected substrates 4a-c. 
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4.2.3.1 N-tert-butoxycarbonyl-β-alanine N′-(2-propyl-1,3-dioxo-2,3-dihydro-1H-
benz[de]isoquinolin-6-yl)hydrazide 4a 
Following the general method, Boc-β-Ala-OH (2.81 g, 14.85 mmol), DCC (1.53 g, 
7.42 mmol), hydrazinobenz[de]isoquinolin-1,3(2H)dione 3a (1.0 g, 3.71 mmol), 
DIPEA (0.48 mL, 3.71 mmol), and DMAP (0.23 g, 1.88 mmol) were reacted to give 
the title compound as a light yellow chalky powder (0.34 g, 21%); mp 193-195 °C; 1H 
NMR (400 MHz, (CD3)2CO) δH 9.17 (1H, broad s, amide NH), 8.54 (1H, dd, J = 8.4 
Hz, 1.2 Hz, H-7), 8.43 (1H, dd, J = 7.6 Hz, 1.2 Hz, H-9), 8.34 (1H, d, J = 8.4 Hz, H-
4), 7.60 (1H, dd, J = 8.4 Hz, 7.6 Hz, H-8), 7.11 (1H, d, J = 8.4 Hz, H-5), 6.08 (1H, 
broad s, carbamate NH), 4.075-4.04 (2H, m, H-1′), 3.44 (2H, q, J = 6.8 Hz, alanine β 
CH2), 2.66 (2H, t, J = 6.8 Hz, alanine α CH2), 1.72 (2H, sextet, J = 7.6 Hz, H-2′), 1.45 
(9H, s, C(CH3)3), 0.965 (3H, t, J = 7.6 Hz, H-3′); 13C NMR (100 MHz, (CD3)2CO) δC 
172.9 (C=O, amide CO), 165.6 (C=O, C-1), 165.1 (C=O, C-3), 157.6 (C=O, 
carbamate CO), 152.1 (quat., C-6), 134.9 (CH, C-4), 132.3 (CH, C-9), 131.1 (quat., 
C-3b), 129.0 (CH, C-7), 127.0 (CH, C-8), 124.7 (quat., C-9a), 121.5 (quat., C-6a), 
114.6 (quat., C-3a), 107.6 (CH, C-5), 79.8 (quat., OC(CH3)3), 43.0 (CH2, C-1′), 38.7 
(CH2, alanine β CH2), 35.9 (CH2, alanine α CH2), 29.7 (3 × CH3, (CH3)3), 23.1 (CH2, 
C-2′), 12.8 (CH3, C-3′); FT-IR (neat, cm-1): 3336 (NH), 3325 (NH), 3279 (NH), 1684 
(C=O), 1655 (amide I), 1647 (C=O), 1585 (amide II), 1528 (C=C); ESI-MS: m/z 442 
(MH+) 
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4.2.3.2 N-tert-butoxycarbonyl-β-alanine N′-(2-pentyl-1,3-dioxo-2,3-dihydro-1H-
benz[de]isoquinolin-6-yl)hydrazide 4b 
Following the general method, Boc-β-Ala-OH (2.04 g, 10.76 mmol), DCC (1.11 g, 
5.38 mmol), hydrazinobenz[de]isoquinolin-1,3(2H)dione 3b (0.80 g, 2.69 mmol), 
DIPEA (0.47 mL, 2.69 mmol), and DMAP (0.16 g, 1.31 mmol) were reacted to give 
the title compound as a yellow-brown solid (0.237 g, 19%); mp 150-154 °C; 1H NMR 
(400 MHz, (CD3)2CO) δH 9.49 (1H, broad s, NH), 9.08 (1H, broad s, NH), 8.38 (1H, 
dd, J = 8.4 Hz, 0.8 Hz, H-7), 8.29-8.26 (2H, m, H-4, H-9), 7.39 (1H, dd, J = 8.4 Hz, 
7.6 Hz, H-8), 7.06 (1H, d, J = 8.0 Hz, H-5), 6.13 (1H, broad s, carbamate NH), 4.07 
(2H, t, J = 7.6 Hz, H-1′), 3.47 (2H, q, J = 6.4 Hz, alanine β CH2), 2.70 (2H, t, J = 6.4 
Hz, alanine α CH2), 1.72 (2H, quintet, J = 7.6 Hz, H-2′), 1.46 (9H, s, C(CH3)3), 1.41-
1.38 (4H, m, H-3′, H-4′), 0.93 (3H, t, J = 7.2 Hz, H-5′); 13C NMR (100 MHz, 
(CD3)2CO) δC 173.4 (C=O, amide CO), 165.5 (C=O, C-1), 165.0 (C=O, C-3), 157.7 
(C=O, carbamate CO), 151.9 (quat., C-6), 134.8 (CH, C-4), 131.9 (CH, C-9), 130.8 
(quat., C-3b), 128.8 (CH, C-7), 126.8 (CH, C-8), 124.4 (quat., C-9a), 121.2 (quat., C-
6a), 114.6 (quat., C-3a), 107.3 (CH, C-5), 80.0 (quat., OC(CH3)3), 41.4 (CH2, C-1′), 
38.7 (CH2, alanine β CH2), 36.0 (CH2, alanine α CH2), 31.1 (CH2, C-3′), 29.7 (3 × 
CH3, (CH3)3), 29.5 (CH2, C-2′), 24.1 (CH2, C-4′), 15.3 (CH3, C-5′); FT-IR (neat, cm-
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1): 3357 (NH), 3312 (NH), 3221 (NH), 1688 (C=O), 1674 (amide I), 1639 (C=O), 
1614 (amide II), 1587 (C=C), 1519 (C=C); ESI-MS: m/z 469 (MH+) 
 
 
4.2.3.3 N-tert-butoxycarbonyl-β-alanine N′-(2-benzyl-1,3-dioxo-2,3-dihydro-1H-
benz[de]isoquinolin-6-yl)hydrazide 4c 
Following the general method, Boc-β-Ala-OH (1.43 g, 7.56 mmol), DCC (0.78 g, 
3.78 mmol), hydrazinobenz[de]isoquinolin-1,3(2H)dione 3c (0.60 g, 1.89 mmol), 
DIPEA (0.33 mL, 1.89 mmol), and DMAP (0.12 g, 0.98 mmol) were reacted to give 
the title compound as a yellow solid (0.313 g, 34%); mp 175-177 °C; 1H NMR (400 
MHz, (CD3)2CO) δH 9.54 (1H, broad s, NH), 8.89 (1H, broad s, NH), 8.54 (1H, dd, J 
= 8.4 Hz, 0.8 Hz, H-7), 8.43 (1H, dd, J = 7.2 Hz, 0.8 Hz, H-9), 8.35 (1H, d, J = 8.4 
Hz, H-4), 7.58 (1H, dd, J = 8.4 Hz, 7.2 Hz, H-8), 7.47-7.44 (2H, m, H-2′, H-6′), 7.31-
7.27 (2H, m, H-3′, H-5′), 7.23-7.19 (1H, m, H-4′), 7.11 (1H, d, J = 8.4 Hz, H-5), 6.09 
(1H, s, carbamate NH), 5.32 (2H, s, CH2), 3.44 (2H, t, J = 6.8 Hz, alanine β CH2), 
2.67 (2H, t, J = 6.8 Hz, alanine α CH2), 1.45 (9H, s, C(CH3)3);13C NMR (100 MHz, 
(CD3)2CO) δC 174.1 (C=O, amide CO), 165.7 (C=O, C-1), 165.1 (C=O, C-3), 157.6 
(C=O, carbamate CO), 152.3 (quat., C-6), 140.2 (quat., C-1′), 135.2 (CH, C-4), 132.6 
(CH, C-9), 131.1 (quat., C-3b), 130.04 (2 × CH, C-3′, C-5′), 130.01 (2 × CH, C-2′, C-
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6′), 129.3 (CH, C-7), 128.8 (CH, C-4′), 127.0 (CH, C-8), 124.5 (quat., C-9a), 121.4 
(quat., C-6a), 114.4 (quat., C-3a), 107.7 (CH, C-5), 79.9 (quat., OC(CH3)3), 44.7 
(CH2), 38.5 (CH2, alanine β CH2), 35.9 (CH2, alanine α CH2), 29.7 (3 × CH3, (CH3)3); 
FT-IR (neat, cm-1): 3387 (NH), 3318 (NH), 3298 (NH), 1684 (C=O), 1653 (amide I), 
1647 (C=O), 1638 (amide II), 1578 (C=C), 1541 (C=C), 1521 (C=C), 1508 (C=C); 
ESI-MS: m/z 511 (MNa+) 
 
 
4.2.4 General method for the removal of Boc-protecting group 
Boc-protected substrates 4a-c were dissolved in DCM (5 mL) and the solution cooled 
to 0 °C in an ice bath. DCM/TFA (5 drops of 1:1 mixture) was added to this solution 
which was allowed to stir for 2 hours while warming to room temperature. The 
solvent and excess TFA were removed in vacuo after the addition of methanol (50 
mL). The reaction vessel was then cooled at -80 °C overnight to give the final 
substrate 5a-c as a TFA salt. 
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4.2.4.1  β-Alanine N′-(2-propyl-1,3-dioxo-2,3-dihydro-1H-benz[de]isoquinolin-6-
yl)hydrazide, trifluoroacetate 5a  
Following the general method, 4a (200 mg, 0.45 mmol) was used to obtain the title 
compound as light orange crystals (184.1 mg, 89%); mp 134-136 °C; 1H NMR (400 
MHz, CD3OD) δH 8.55 (1H, d, J = 7.6 Hz, H-7), 8.51 (1H, d, J = 8.8 Hz, H-9), 8.40 
(1H, d, J = 8.4 Hz, H-4), 7.74-7.70 (1H, m, H-8), 7.03 (1H, d, J = 8.4 Hz, H-5), 4.11-
4.07 (2H, m, H-1′), 3.35-3.31 (2H, m, alanine β CH2), 2.86 (2H, t, J = 6.8 Hz, alanine 
α CH2), 1.73 (2H, sextet, J = 7.6 Hz, C-2′), 0.99 (3H, t, J = 7.6 Hz, C-3′); 13C NMR 
(100 MHz, CD3OD) δc 172.3 (C=O, amide CO), 166.0 (C=O, C-1), 165.7 (C=O, C-3), 
151.7 (quat., C-6), 135.0 (CH, C-4), 132.4 (CH, C-9), 130.7 (quat., C-3b), 129.1 (CH, 
C-7), 126.4 (CH, C-8), 123.7 (quat., C-9a), 120.9 (quat., C-6a), 113.4 (quat., C-3a), 
106.5 (CH, C-5), 42.7 (CH2, C-1′), 36.8 (CH2, alanine β CH2), 31.3 (CH2, alanine α 
CH2), 22.5 (CH2, C-2′), 11.8 (CH3, C-3′); FT-IR (neat, cm-1): 3482 (NH), 3252 (NH), 
1687 (C=O), 1672 (amide I), 1646 (C=O), 1614 (amide II), 1582 (C=C), 1533 (C=C); 
ESI-MS: m/z 341 (M+); HRMS calcd. for C18H21N4O3: 341.1608. Found: 341.1605 
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4.2.4.2 β-Alanine N′-(2-pentyl-1,3-dioxo-2,3-dihydro-1H-benz[de]isoquinolin-6-
yl)hydrazide, trifluoroacetate 5b  
Following the general method, 4b (150 mg, 0.32 mmol) was used to obtain the title 
compound as a bright yellow solid (144.9 mg, 94%); mp 122-127 °C; 1H NMR (400 
MHz, CD3OD) δH 8.51 (1H, dd, J = 7.2 Hz, 0.8 Hz, H-7), 8.47 (1H, dd, J = 8.4 Hz, 
0.8 Hz, H-9), 8.38 (1H, d, J = 8.4 Hz, H-4), 7.68 (1H, dd, J = 8.4 Hz, 7.2 Hz, H-8), 
7.01 (1H, d, J = 8.4 Hz, H-5), 4.10 (2H, t, J = 7.6 Hz, H-1′), 3.34-3.31 (2H, m, alanine 
β CH2), 2.87 (2H, t, J = 6.4 Hz, alanine α CH2), 1.69 (2H, quintet, J = 7.6 Hz, H-2′), 
1.42-1.37 (4H, m, H-3′, H-4′), 0.92 (3H, t, J = 6.8 Hz, H-5′); 13C NMR (100 MHz, 
CD3OD) δc 172.3 (C=O, amide CO), 166.0 (C=O, C-1), 165.6 (C=O, C-3), 151.7 
(quat., C-6), 134.9 (CH, C-4), 132.4 (CH, C-9), 130.7 (quat., C-3b), 129.1 (CH, C-7), 
126.4 (CH, C-8), 123.7 (quat., C-9a), 120.9 (quat., C-6a), 113.4 (quat., C-3a), 106.5 
(CH, C-5), 41.2 (CH2, C-1′), 36.8 (CH2, alanine β CH2), 31.2 (CH2, alanine α CH2), 
30.4 (CH2, C-3′), 28.9 (CH2, C-2′), 23.5 (CH2, C-4′), 14.4 (CH3, C-5′); FT-IR (Nujol, 
cm-1): 3392 (NH), 3336 (NH), 3197 (NH), 1707 (C=O), 1674 (amide I), 1638 (C=O), 
1615 (amide II), 1585 (C=C), 1532 (C=C); ESI-MS: m/z 369 (M+); HRMS calcd. for 
C20H25N4O3: 369.1921 Found: 369.1918 
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4.2.4.3 β-Alanine N′-(2-benzyl-1,3-dioxo-2,3-dihydro-1H-benz[de]isoquinolin-6-
yl)hydrazide, trifluoroacetate 5c  
Following the general method, 4c (100 mg, 0.21 mmol) was used to obtain the title 
compound as an orange solid (98.3 mg, 96%); mp 131-133 °C; 1H NMR (400 MHz, 
CD3OD) δH 8.52 (1H, dd, J = 7.6 Hz, 0.8 Hz, H-7), 8.48 (1H, J = 8.4 Hz, 0.8 Hz, H-
9), 8.39 (1H, d, J = 8.4 Hz, H-4), 7.68 (1H, dd, J = 8.4 Hz, 7.6 Hz, H-8), 7.42-7.39 
(2H, m, H-2′, H-6′), 7.295-7.26 (2H, m, H-3′, H-5′), 7.22-7.19 (1H, m, H-4′), 7.01 
(1H, d, J = 8.4 Hz, H-5), 5.30 (2H, s, CH2), 3.33-3.31 (2H, m, alanine β CH2), 2.87 
(2H, t, J = 6.8 Hz, alanine α CH2); 13C NMR (100 MHz, (CD3OD) δc 172.3 (C=O, 
amide CO), 166.0 (C=O, C-1), 165.6 (C=O, C-3), 151.8 (quat., C-6), 139.1 (quat., C-
1′), 135.2 (CH, C-4), 132.6 (CH, C-9), 130.8 (quat., C-3b), 129.4 (2 × CH, C-3′, C-5′), 
129.3 (CH, C-7), 129.2 (2 × CH, C-2′, C-6′), 128.3 (CH, C-4′), 126.5 (CH, C-8), 
123.6 (quat., C-9a), 120.9 (quat., C-6a), 113.2 (quat., C-3a), 106.6 (CH, C-5), 44.3 
(CH2), 36.8 (CH2, alanine β CH2), 31.2 (CH2, alanine α CH2); FT-IR (Nujol, cm-1): 
3462 (NH), 3219 (NH), 1701 (C=O), 1684 (amide I), 1640 (C=O), 1614 (amide II), 
1577 (C=C); ESI-MS: m/z 389 (M+); HRMS calcd. for C22H21N4O3: 389.1608. Found: 
389.1606 
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4.2.5  General method for the coupling of hydrazides to aryl aldehydes 
The hydrazides 3a-c (1 equiv.) and arylaldehydes (1.1 equiv.) were dissolved in 
ethanol (25 mL) and stirred at 80 °C for 2 hours with five drops of glacial acetic acid 
as a catalyst. The solution was then allowed to cool and the formed precipitate was 
collected by filtration to obtain final compounds 6-10 without further purification. 
 
4.2.5.1 6-(2-Benzylidenehydrazinyl)-2-propyl-1H-benzo[de]isoquinoline-1,3(2H)-
dione 6a 
Using the general method, hydrazinobenz[de]isoquinolin-1,3(2H)dione 3a (200 mg, 
0.74 mmol) and benzaldehyde (0.084 mL, 0.82 mmol) were reacted to obtain the title 
compound as orange crystals (202.7 mg, 76%); mp 213 °C; 1H NMR (400 MHz, 
(CD3)2CO) δH 10.65 (1H, s, NH), 8.67 (1H, d, J = 8.4 Hz, H-7), 8.52 (1H, d, J = 7.2 
Hz, H-9), 8.47 (1H, d, J = 8.4 Hz, H-4), 8.39 (1H, s, N=CH), 7.87 (1H, d, J = 8.4 Hz, 
H-5), 7.83 (2H, d, J = 7.6 Hz, H-2″, H-6″), 7.76-7.72 (1H, m, H-8), 7.49-7.40 (3H, m, 
H-3″, H-4″, H-5″), 4.07 (2H, t, J = 7.6 Hz, H-1′), 1.72 (2H, sextet, J = 7.6 Hz, CH-2′), 
0.97 (3H, t, J = 7.6 Hz, CH-3′); 13C NMR (100 MHz, (CD3)2CO) δC 165.7 (C=O, C-
1), 165.1 (C=O, C-3), 148.1 (quat., C-6), 145.5 (CH, N=CH), 136.9 (quat., C-1″), 
135.1 (CH, C-4), 132.5 (CH, C-9), 131.5 (quat., C-3b), 131.4 (CH, C-4″), 130.7 (2 × 
CH, C-3″, C-5″), 128.9 (CH, C-7), 128.7 (2 × CH, C-2″, C-6″), 126.9 (CH, C-8), 
124.9 (quat., C-9a), 120.9 (quat., C-6a), 114.3 (quat., C-3a), 109.1 (CH, C-5), 43.0 
(CH2, C-1′), 23.1 (CH2, C-2′), 12.8 (CH3, C-3′); FT-IR (Nujol, cm-1): 3266 (NH), 
1687 (C=O), 1635 (C=O), 1601 (C=N), 1585 (C=C), 1558 (C=C), 1539 (C=C); ESI-
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MS: m/z 358 (MH+); Anal. Calcd. for 4(C22H19N3O2).H2O: C, 73.01; H, 5.43; N, 
11.61. Found:  C, 73.16; H, 5.51; N, 11.44. 
 
 
4.2.5.2 6-(2-Benzylidenehydrazinyl)-2-pentyl-1H-benzo[de]isoquinoline-1,3(2H)-
dione 6b 
Using the general method, hydrazinobenz[de]isoquinolin-1,3(2H)dione 3b (200 mg, 
0.67 mmol) and benzaldehyde (0.075 mL, 0.74 mmol) were reacted to obtain bright 
orange crystals (87.7 mg, 34%); mp 230-232 °C; 1H NMR (400 MHz, (CD3)2CO) δH 
10.65 (1H, s, NH), 8.68 (1H, dd, J = 8.4 Hz, 1.2 Hz, H-7), 8.53 (1H, dd, J = 7.2 Hz, 
1.2 Hz, H-9), 8.47 (1H, d, J = 8.4 Hz, H-4), 8.39 (1H, s, N=CH), 7.87 (1H, d, J = 8.4 
Hz, H-5), 7.84-7.82 (2H, m, H-2″, H-6″), 7.75 (1H, dd, J = 8.4 Hz, 7.2 Hz, H-8), 
7.50-7.40 (3H, m, H-3″, H-4″, H-5″), 4.12-4.08 (2H, m, H-1′), 1.71 (2H, quintet, J = 
7.2 Hz, H-2′), 1.41-1.36 (4H, m, H-3′, H-4′), 0.93-0.90 (3H, m, H-5′); 13C NMR (100 
MHz, (CD3)2CO) δC 165.7 (C=O, C-1), 165.1 (C=O, C-3), 148.1 (quat., C-6), 145.5 
(CH, N=CH), 136.9 (quat., C-1″), 135.1 (CH, C-4), 132.5 (CH, C-9), 131.5 (quat., C-
3b), 131.4 (CH, C-4″), 130.7 (2 × CH, C-3″, C-5″), 128.9 (CH, C-7), 128.7 (2 × CH, 
C-2″, C-6″), 126.9 (CH, C-8), 124.9 (quat., C-9a), 120.9 (quat., C-6a), 114.3 (quat., 
C-3a), 109.1 (CH, C-5), 41.4 (CH2, C-1′), 31.0 (CH2, C-3′), 29.55 (CH2, C-2′), 24.1 
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(CH2, C-4′), 15.3 (CH3, C-5′); FT-IR (Nujol, cm-1): 3283 (NH), 1682 (C=O), 1639 
(C=O), 1615 (C=N), 1585 (C=C), 1557 (C=C), 1506 (C=C); ESI-MS: m/z 386 (MH+); 
Anal. Calcd. for C24H23N3O2: C, 74.78; H, 6.01; N, 10.90. Found: C, 74.71; 6.01; N, 
10.86. 
 
 
4.2.5.3 6-(2-Benzylidenehydrazinyl)-2-benzyl-1H-benzo[de]isoquinoline-1,3(2H)-
dione 6c 
Using the general method, hydrazinobenz[de]isoquinolin-1,3(2H)dione 3c (200 mg, 
0.63 mmol) and benzaldehyde (0.071 mL, 0.69 mmol) were reacted to obtain the title 
compound as orange crystals (141.2 mg, 55%); mp 247-248 °C; 1H NMR (400 MHz, 
(CD3)2SO) δH 11.54 (1H, s, NH), 8.82 (1H, d, J = 8.4 Hz, H-7), 8.51 (1H, d, J = 7.2 
Hz, H-9), 8.47 (1H, s, N=CH), 8.40 (1H, d, J = 8.4 Hz, H-4), 7.83-7.78 (3H, m, H-8, 
H-2″, H-6″), 7.76 (1H, d, J = 8.4 Hz, H-5), 7.48 (2H, t, J = 7.2 Hz, H-3″, H-5″), 7.44-
7.41 (1H, m, H-4″), 7.35-7.28 (4H, m, H-2′, H-3′, H-5′, H-6′), 7.22 (1H, t, J = 7.2 Hz, 
H-4′), 5.24 (2H, s, CH2); 13C NMR (100 MHz, (CD3)2SO) δC 163.7 (C=O, C-1), 163.0 
(C=O, C-3), 146.8 (quat., C-6), 144.2 (CH, N=CH), 137.7 (quat., C-1′), 134.6 (quat., 
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C-1″), 133.8 (CH, C-4), 131.1 (CH, C-9), 129.6 (CH, C-4″), 129.3 (quat., C-3b), 
128.9 (2 × CH, C-3″, C-5″), 128.5 (CH, C-7), 128.3 (2 × CH, C-3′, C-5′), 127.5 (2 × 
CH, C-2′, C-6′), 126.9 (CH, C-4′), 126.7 (2 × CH, C-2″, C-6″), 125.0 (CH, C-8), 
121.8 (quat., C-9a), 118.7 (quat., C-6a), 110.6 (quat., C-3a), 107.0 (CH, C-5), 42.6 
(CH2); FT-IR (Nujol, cm
-1): 3346 (NH), 1683 (C=O), 1636 (C=O), 1578 (C=N), 1539 
(C=C); ESI-MS: m/z 406 (MH+); Anal. Calcd. for C26H19N3O2: C, 77.02; H, 4.72; N, 
10.36. Found: C, 77.00; H, 4.69; N, 10.34. 
 
 
4.2.5.4 6-(2-(4-Chlorobenzylidene)hydrazinyl)-2-propyl-1H-benzo[de]isoquino 
line-1,3(2H)-dione 7a 
Using the general method, hydrazinobenz[de]isoquinolin-1,3(2H)dione 3a (200 mg, 
0.74 mmol) and 4-chlorobenzaldehyde (114.8 mg, 0.82 mmol) were reacted to obtain 
the title compound as orange crystals (224.2 mg, 77%); mp 255-258 °C; 1H NMR 
(400 MHz, (CD3)2CO) δH 10.73 (1H, s, NH), 8.68 (1H, dd, J = 8.4 Hz, 0.8 Hz, H-7), 
8.53 (1H, dd, J = 7.2 Hz, 0.8 Hz, H-9), 8.48 (1H, d, J = 8.4 Hz, H-4), 8.38 (1H, s, 
N=CH), 7.88 (1H, d, J = 8.4 Hz, H-5), 7.85 (2H,BB′ of AA′BB′, H-2″, H-6″), 7.76 
(1H, dd, J = 8.4 Hz, 7.2 Hz, H-8), 7.50 (2H, AA′ of AA′BB′, H-3″, H-5″), 4.07 (2H, t, 
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J = 7.6 Hz, H-1′), 1.72 (2H, sextet, J = 7.6 Hz, H-2′), 0.97 (3H, t, J = 7.6 Hz, H-3′); 
13C NMR (100 MHz, (CD3)2CO) δC 165.7 (C=O, C-1), 165.1 (C=O, C-3), 147.9 
(quat., C-6),  144.0 (CH, N=CH), 136.4 (quat., C-4″), 135.8 (quat., C-1″), 135.1 (CH, 
C-4), 132.6 (CH, C-9), 131.5 (quat., C-3b), 130.8 (2 × CH, C-3″, C-5″), 130.1 (2 × 
CH, C-2″, C-6″), 128.9 (CH, C-7), 127.0 (CH, C-8), 124.9 (quat., C-9a), 121.0 (quat., 
C-6a), 114.6 (quat., C-3a),  109.3 (CH, C-5), 43.0 (CH2, C-1′), 23.1 (CH2, C-2′), 12.8 
(CH3, C-3′); FT-IR (Nujol, cm-1): 3262 (NH), 1687 (C=O), 1635 (C=O), 1616 (C=N), 
1596 (C=C), 1587 (C=C); ESI-MS: m/z 392 (MH+); Anal. Calcd. for 
C22H16ClN3O2.C2H5OH: C, 65.83; H, 5.52; N, 9.60. Found: C, 65.92; H, 5.15; N, 
9.98. 
 
 
4.2.5.5 6-(2-(4-Chlorobenzylidene)hydrazinyl)-2-pentyl-1H-benzo[de]isoquino 
line-1,3(2H)-dione 7b 
Using the general method, hydrazinobenz[de]isoquinolin-1,3(2H)dione 3b (200 mg, 
0.67 mmol) and 4-chlorobenzaldehyde (104.0 mg, 0.74 mmol) were reacted to obtain 
the title compound as an orange powder (257.8 mg, 91%); mp 196-197 °C; 1H NMR 
(400 MHz, (CD3)2CO) δH 10.68 (1H, s, NH), 8.63 (1H, d, J = 8.4 Hz, H-7), 8.50 (1H, 
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d, J = 7.2 Hz, H-9), 8.44 (1H, d, J = 8.4 Hz, H-4), 8.34 (1H, s, N=CH), 7.84-7.81 (3H, 
m, H-5, H-2″, H-6″), 7.74-7.70 (1H, m, H-8), 7.48 (2H, d, J = 8.4 Hz, H-3″, H-5″), 
4.08 (2H, t, J = 7.6 Hz, H-1′), 1.69 (2H, quintet, J = 7.2 Hz, H-2′), 1.39-1.36 (4H, m, 
H-3′, H-4′), 0.93-0.89 (3H, m, H-5′); 13C NMR (100 MHz, (CD3)2CO) δC 165.6 (C=O, 
C-1), 165.0 (C=O, C-3), 147.8 (quat., C-6),  144.0 (CH, N=CH), 136.4 (quat., C-4″), 
135.8 (quat., C-1″), 135.0 (CH, C-4), 132.5 (CH, C-9), 131.4 (quat., C-3b), 130.8 (2 × 
CH, C-3″, C-5″), 130.1 (2 × CH, C-2″, C-6″), 128.9 (CH, C-7), 126.9 (CH, C-8), 
124.9 (quat., C-9a), 120.9 (quat., C-6a), 114.5 (quat., C-3a),  109.2 (CH, C-5), 41.4 
(CH2, C-1′), 31.0 (CH2, C-3′), 29.5 (CH2, C-2′), 24.1 (CH2, C-4′), 15.3 (CH3, C-5′); 
FT-IR (neat, cm-1): 3248 (NH), 1680 (C=O), 1627 (C=O), 1610 (C=N), 1570 (C=C), 
1560 (C=C); ESI-MS: m/z 420 (MH+); Anal. Calcd. For C24H22ClN3O2.H2O: C, 65.83; 
H, 5.52; N, 9.60. Found: C, 65.85; H, 5.49; N, 9.60. 
 
 
4.2.5.6 6-(2-(4-Chlorobenzylidene)hydrazinyl)-2-benzyl-1H-benzo[de]isoquino 
line-1,3(2H)-dione 7c 
Using the general method, hydrazinobenz[de]isoquinolin-1,3(2H)dione 3c (200 mg, 
0.63 mmol) and 4-chlorobenzaldehyde (97.4 mg, 0.69 mmol) were reacted to obtain 
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the title compound as an orange powder (183.1 mg, 81%); mp 272-275 °C; 1H NMR 
(400 MHz, (CD3)2SO) δH 11.59 (1H, s, NH), 8.81 (1H, d, J = 8.4 Hz, H-7), 8.50 (1H, 
d, J = 7.2 Hz, H-9), 8.44 (1H, s, N=CH), 8.40 (1H, d, J = 8.4 Hz, H-4), 7.85-7.79 (3H, 
H-8, H-2″, H-6″), 7.76 (1H, d, J = 8.4 Hz, H-5), 7.53 (2H, d, J = 8.4 Hz, H-3″, H-5″), 
7.35-7.28 (4H, m, H-2′, H-3′, H-5′, H-6′), 7.23 (1H, t, J = 7.2 Hz, H-4′), 5.23 (2H, s, 
CH2); 
13C NMR (100 MHz, (CD3)2SO) δC 163.7 (C=O, C-1), 162.9 (C=O, C-3), 146.6 
(quat., C-6), 142.7 (CH, N=CH), 137.7 (quat., C-1′), 133.8 (quat., C-4″), 133.7 (CH, 
C-4), 133.5 (quat., C-1″), 131.1 (CH, C-9), 129.2 (quat., C-3b), 128.9 (2 × CH, C-3″, 
C-5″), 128.5 (CH, C-7), 128.3 (4 × CH, C-3′, C-5′, C-2″C, C-6″), 127.5 (2 × CH, C-
2′, C-6′), 126.9 (CH, C-4′), 125.05 (CH, C-8), 121.8 (quat., C-9a), 118.7 (quat., C-6a), 
110.8 (quat., C-3a), 107.1 (CH, C-5), 42.6 (CH2); FT-IR (Nujol, cm
-1): 3313 (NH), 
1688 (C=O), 1642 (C=O), 1612 (C=N), 1584 (C=C), 1564 (C=C); ESI-MS: m/z 440 
(MH+); Anal. Calcd. for C26H18ClN3O2: C, 70.99; H, 4.12; N, 9.55. Found: C, 71.22; 
H, 4.15; N, 9.54. 
 
  
4.2.5.7 6-(2-(4-Methoxybenzylidene)hydrazinyl)-2-propyl-1H-benzo[de]isoquino 
line-1,3(2H)-dione 8a 
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Using the general method, hydrazinobenz[de]isoquinolin-1,3(2H)dione 3a (200 mg, 
0.74 mmol) and p-anisaldehyde (0.099 mL, 0.82 mmol) were reacted to obtain the 
title compound as orange-red crystals (265.7 mg, 92%); mp 226-227 °C; 1H NMR 
(400 MHz, (CD3)2CO) δH 10.54 (1H, s, NH), 8.67 (1H, dd, J = 8.4 Hz, 0.8 Hz, H-7), 
8.52 (1H, dd, J = 7.2 Hz, 0.8 Hz, H-9), 8.46 (1H, d, J = 8.8 Hz, H-4), 8.34 (1H, s, 
N=CH), 7.84 (1H, d, J = 8.4 Hz, H-5), 7.78 (2H, BB′ of AA′BB′, H-2″, H-6″), 7.73 
(1H, dd, J = 8.4 Hz, 7.2 Hz, H-8), 7.03 (2H, AA′ of AA′BB′, H-3″, H-5″), 4.09-4.05 
(2H, m, H-1′), 3.87 (3H, s, OCH3), 1.72 (2H, sextet, J = 7.6 Hz, H-2′), 0.97 (3H, t, J = 
7.6 Hz, H-3′); 13C NMR (100 MHz, (CD3)2CO) δC 165.8 (C=O, C-1), 165.1(C=O, C-
3), 163.0 (quat., C-4″), 148.3 (quat., C-6), 145.6 (CH, N=CH), 135.2 (CH, C-4), 132.5 
(CH, C-9), 131.5 (quat., C-3b), 130.2 (2 × CH, C-2″, C-6″) 129.5 (quat., C-1″), 128.9 
(CH, C-7), 126.7 (CH, C-8), 124.8 (quat., C-9a), 120.9 (quat., C-6a), 116.1 (2 × CH, 
C-3″, C-5″), 113.8 (quat., C-3a), 108.8 (CH, C-5), 56.7 (CH3, OCH3), 42.9 (CH2, C-
1′), 23.1 (CH2, C-2′), 12.8 (CH3, C-3′); FT-IR (Nujol, cm-1): 3244 (NH), 1680 (C=O), 
1635 (C=O), 1602 (C=N), 1587 (C=C), 1516 (C=C); ESI-MS: m/z 388 (MH+); Anal. 
Calcd. for C23H21N3O3: C, 71.30; H, 5.46; N, 10.85. Found: C, 71.12; H, 5.53; N, 
10.76. 
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4.2.5.8 6-(2-(4-Methoxybenzylidene)hydrazinyl)-2-pentyl-1H-benzo[de]isoquino 
line-1,3(2H)-dione 8b 
Using the general method, hydrazinobenz[de]isoquinolin-1,3(2H)dione 3b (200 mg, 
0.67 mmol) and p-anisaldehyde (0.090 mL, 0.74 mmol) were reacted to obtain the 
title compound as an orange-red powder (133.1 mg, 48%); mp 202-204 °C; 1H NMR 
(400 MHz, (CD3)2CO) δH 10.53 (1H, s, NH), 8.67 (1H, dd, J = 8.4 Hz, 0.8 Hz, H-7), 
8.52 (1H, dd, J = 7.2 Hz, 0.8 Hz, H-9), 8.46 (1H, d, J = 8.4 Hz, H-4), 8.34 (1H, s, 
N=CH), 7.83 (1H, d, J = 8.4 Hz, H-5), 7.77 (2H, BB′ of AA′BB′, H-2″, H-6″), 7.73 
(1H, dd, J = 8.4 Hz, 7.2 Hz, H-8), 7.03 (2H, AA′ of AA′BB′, H-3″, H-5″), 4.12-4.08 
(2H, m, H-1′), 3.87 (3H, s, OCH3), 1.70 (2H, quintet, J = 7.2 Hz, H-2′), 1.40-1.36 
(4H, m, H-3′, H-4′), 0.93-0.90 (3H, m, H-5′); 13C NMR (100 MHz, (CD3)2CO) δC 
165.7 (C=O, C-1), 165.1(C=O, C-3), 163.0 (quat., C-4″), 148.3 (quat., C-6), 145.6 
(CH, N=CH), 135.2 (CH, C-4), 132.5 (CH, C-9), 131.5 (quat., C-3b), 130.2 (2 × CH, 
C-2″, C-6″), 129.5 (quat., C-1″), 128.9 (CH, C-7), 126.7 (CH, C-8), 124.8 (quat., C-
9a), 120.9 (quat., C-6a), 116.1 (2 × CH, C-3″, C-5″), 113.8 (quat., C-3a), 108.9 (CH, 
C-5), 56.7 (CH3, OCH3), 41.4 (CH2, C-1′), 31.0 (CH2, C-3′), 29.6 (CH2, C-2′), 24.1 
(CH2, C-4′), 15.3 (CH3, C-5′); FT-IR (neat, cm-1): 3316 (NH), 1684 (C=O), 1636 
(C=O), 1609 (C=N), 1570 (C=C), 1558 (C=C), 1548 (C=C), 1508 (C=C); ESI-MS: 
m/z 416 (MH+); Anal. Calcd. for C25H25N3O3: C, 72.27; H, 6.07; N, 10.11. Found: C, 
72.29; H, 6.13; N, 10.11. 
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4.2.5.9 6-(2-(4-Methoxybenzylidene)hydrazinyl)-2-benzyl-1H-benzo[de]isoquino 
line-1,3(2H)-dione 8c 
Using the general method, hydrazinobenz[de]isoquinolin-1,3(2H)dione 3c (200 mg, 
0.63 mmol) and p-anisaldehyde (0.084 mL, 0.69 mmol) were reacted to obtain the 
title compound as an orange-red powder (207.3 mg, 76%); mp 226-228 °C; 1H NMR 
(400 MHz, (CD3)2SO) δH 11.42 (1H, s, NH), 8.81 (1H, d, J = 8.4 Hz, H-7), 8.50 (1H, 
d, J = 7.2 Hz, H-9), 8.42 (1H, s, N=CH), 8.38 (1H, d, J = 8.4 Hz, H-4), 7.81-7.75 (3H, 
m, H-8, H-2″, H-6″), 7.72 (1H, d, J = 8.4 Hz, H-5), 7.35-7.28 (4H, m, H-2′, H-3′, H-
5′, H-6′), 7.22 (1H, t, J = 7.2 Hz, H-4′), 7.04 (2H, d, J = 8.4 Hz, H-3″, H-5″), 5.23 
(2H, s, CH2), 3.82 (3H, s, OCH3); 
13C NMR (100 MHz, (CD3)2SO) δC 163.7 (C=O, C-
1), 162.9 (C=O, C-3), 160.5 (quat., C-4″), 146.9 (quat., C-6), 144.3 (CH, N=CH), 
137.7 (quat., C-1′), 133.8 (CH, C-4), 131.0 (CH, C-9), 129.3 (quat., C-3b), 128.5 (CH, 
C-7), 128.31 (2 × CH, C-2″, C-6″), 128.25 (2 × CH, C-3′, C-5′), 127.4 (2 × CH, C-2′, 
C-6′), 127.1 (CH, C-1″), 126.9 (CH, C-4′), 124.8 (CH, C-8), 121.8 (quat., C-9a), 
118.5 (quat., C-6a), 114.3 (2 × CH, C-3″, C-5″), 110.1 (quat., C-3a), 106.6 (CH, C-5), 
55.3 (CH3, OCH3), 42.5 (CH2); FT-IR (neat, cm
-1): 3319 (NH), 1684 (C=O), 1636 
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(C=O), 1608 (C=N), 1570 (C=C), 1558 (C=C), 1541 (C=C), 1508 (C=C); ESI-MS: 
m/z 436 (MH+); Anal. Calcd. for C27H21N3O3: C, 74.47; H, 4.86; N, 9.65. Found: C, 
74.22; H, 4.81; N, 9.58. 
 
 
4.2.5.10 6-(2-(4-Dimethylaminobenzylidene)hydrazinyl)-2-propyl-1H-benzo[de] 
isoquinoline-1,3(2H)-dione 9a 
Using the general method, hydrazinobenz[de]isoquinolin-1,3(2H)dione 3a (200 mg, 
0.74 mmol) and 4-dimethylaminobenzaldehyde (121.8 mg, 0.82 mmol) were reacted 
to obtain the title compound as dark purple crystals (237.6 mg, 80%); mp 240-241°C; 
1H NMR (400 MHz, (CD3)2CO) δH 10.41 (1H, s, NH), 8.67 (1H, dd, J = 8.4 Hz, 0.8 
Hz, H-7), 8.51 (1H, dd, J = 7.2 Hz, 0.8 Hz, H-9), 8.45 (1H, d, J = 8.4 Hz, H-4), 8.28 
(1H, s, N=CH), 7.79 (1H, d, J = 8.4 Hz, H-5), 7.71 (1H, dd, J = 8.4 Hz, 7.2 Hz, H-8), 
7.66 (2H, m, BB′ of AA′BB′, J = 8.8 Hz, H-2″, H-6″), 6.81 (2H, m, AA′ of AA′BB′, J 
= 8.8 Hz, H-3″, H-5″), 4.09-4.05 (2H, m, H-1′), 3.04 (6H, s, N(CH3)2), 1.72 (2H, 
sextet, J = 7.6 Hz, H-2′), 0.97 (3H, t, J = 7.6 Hz, H-3′); 13C NMR (100 MHz, 
(CD3)2CO) δC 165.8 (C=O, C-1), 165.1 (C=O, C-3), 153.6 (quat., C-4″), 148.5 (quat., 
C-6), 146.9 (CH, N=CH), 135.35 (CH, C-4), 132.4 (CH, C-9), 131.6 (quat., C-3b), 
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130.1 (2 × CH, C-2″, C-6″), 129.0 (CH, C-7), 126.5 (CH, C-8), 124.8 (quat., C-9a), 
124.4 (quat., C-1″), 120.8 (quat., C-6a), 113.8 (2 × CH, C-3″, C-5″), 113.1 (quat., C-
3a), 108.5 (CH, C-5), 42.9 (CH2, C-1′), 41.3 (2 × CH3, N(CH3)2), 23.1 (CH2, C-2′), 
12.8 (CH3, C-3′); FT-IR (Nujol, cm-1): 3258 (NH), 1680 (C=O), 1628 (C=O), 1611 
(C=N), 1586 (C=C), 1527 (C=C); ESI-MS: m/z 401 (MH+); Anal. Calcd. for 
C24H24N4O2: C, 71.98; H, 6.04; N, 13.99. Found: C, 71.87; H, 6.22; N, 13.83. 
 
 
4.2.5.11 6-(2-(4-Dimethylaminobenzylidene)hydrazinyl)-2-pentyl-1H-benzo[de] 
isoquinoline-1,3(2H)-dione 9b 
Using the general method, hydrazinobenz[de]isoquinolin-1,3(2H)dione 3b (200 mg, 
0.67 mmol) and 4-dimethylaminobenzaldehyde (121.8 mg, 0.74 mmol) were reacted 
to obtain a dark purple powder (60.0 mg, 21%); mp 199-202 °C; 1H NMR (400 MHz, 
(CD3)2CO) δH 10.68 (1H, s, NH), 8.74 (1H, dd, J = 8.4 Hz, 0.8 Hz, H-7), 8.50 (1H, 
dd, J = 7.2 Hz, 0.8 Hz, H-9), 8.43 (1H, d, J = 8.4 Hz, H-4), 8.33 (1H, s, N=CH), 7.78 
(1H, d, J = 8.4 Hz, H-5), 7.70 (1H, dd, J = 8.4 Hz, 7.2 Hz, H-8), 7.65 (2H, BB′ of 
AA′BB′, H-2″, H-6″), 6.79 (2H, AA′ of AA′BB′, H-3″, H-5″), 4.12-4.09 (2H, m, H-
1′), 3.03 (6H, s, N(CH3)2), 1.70 (2H, quintet, J = 7.2 Hz, H-2′), 1.41-1.37 (4H, m, H-
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3′, H-4′), 0.93-0.90 (3H, m, H-5′); 13C NMR (100 MHz, (CD3)2SO) δC 163.6 (C=O, 
C-1), 162.8 (C=O, C-3), 151.2 (quat., C-4″), 145.4 (CH, N=CH), 135.9 (quat., C-6), 
133.6 (CH, C-4), 130.6 (CH, C-9), 129.3 (quat., C-3b), 128.2 (CH, C-7), 128.1 (2 × 
CH, C-2″, C-6″), 124.5 (CH, C-8), 121.9  (quat., C-1″), 121.8 (quat., C-9a), 118.5 
(quat., C-6a), 111.9 (2 × CH, C-3″, C-5″), 109.4 (quat., C-3a), 106.2 (CH, C-5), 39.8 
(2 × CH3, N(CH3)2), 38.9 (CH2, C-1′), 28.7 (CH2, C-3′), 27.2 (CH2, C-2′), 21.8 (CH2, 
C-4′), 13.8 (CH3, C-5′); FT-IR (Nujol, cm-1): 3309 (NH), 1679 (C=O), 1639 (C=O), 
1613 (C=N), 1585 (C=C), 1572 (C=C), 1527 (C=C); ESI-MS: m/z 429 (MH+); Anal. 
Calcd. for 4(C26H28N4O2).3H2O : C, 70.57; H, 6.61; N, 12.78. Found: C, 70.56; H, 
6.57; N, 12.48. 
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4.2.5.12 6-(2-(4-Dimethylaminobenzylidene)hydrazinyl)-2-propyl-1H-benzo[de] 
isoquinoline-1,3(2H)-dione 9c 
Using the general method, hydrazinobenz[de]isoquinolin-1,3(2H)dione 3c (200 mg, 
0.63 mmol) and 4-dimethylaminobenzaldehyde (103.4 mg, 0.69 mmol) were reacted 
to obtain the title compound as a dark purple powder (202.7 mg, 72%); mp 227-230 
°C; 1H NMR (400 MHz, (CD3)2SO) δH 11.31 (1H, s, NH), 8.82 (1H, dd, J = 8.4 Hz, 
0.8 Hz, H-7), 8.50 (1H, dd, J = 7.6 Hz, 0.8 Hz, H-9), 8.39-8.37 (2H, m, H-4, N=CH), 
7.78 (1H, dd, J = 8.4 Hz, 7.6 Hz, H-8), 7.68 (1H, d, J = 8.8 Hz, H-5), 7.64 (2H, BB′ of 
AA′BB′, H-2″, H-6″), 7.36-7.28 (4H, m, H-2′, H-3′, H-5′, H-6′), 7.25-7.20 (1H, m, H-
4′), 6.79 (2H, AA′ of AA′BB′, H-3″, H-5″), 5.24 (2H, s, CH2), 2.99 (6H, s, N(CH3)2); 
13C NMR (100 MHz, (CD3)2SO) δC 163.9 (C=O, C-1), 163.1 (C=O, C-3), 151.4 
(quat., C-4″), 147.1 (quat., C-6), 145.7 (CH, N=CH), 137.9 (quat., C-1′), 134.1 (CH, 
C-4), 131.2 (CH, C-9), 129.5 (quat., C-3b), 128.6 (CH, C-7), 128.5 (2 × CH, C-3′, C-
5′), 128.3 (2 × CH, C-2″, C-6″), 127.6 (2 × CH, C-2′, C-6′), 127.1 (CH, C-4′), 124.9 
(CH, C-8), 121.9 (quat., C-1″), 121.8 (quat., C-9a), 118.6 (quat., C-6a), 112.0 (2 × 
CH, C-3″, C-5″), 109.6 (quat., C-3a), 106.5 (CH, C-5), 42.7 (CH2), 39.9 (2 × CH3, 
N(CH3)2); FT-IR (Nujol, cm
-1): 3243 (NH), 1677 (C=O), 1627 (C=O), 1604 (C=N), 
1588 (C=C), 1564 (C=C), 1527 (C=C); ESI-MS: m/z 449 (MH+); Anal. Calcd. for 
C28H24N4O2.H2O: C, 72.09; H, 5.62; N, 12.01. Found:  C, 71.89; H, 5.52; N, 12.02. 
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4.2.5.13 6-(2-Cinnamylidenehydrazinyl)-2-propyl-1H-benzo[de]isoquinoline-1,3 
(2H)-dione 10a 
Using the general method, hydrazinobenz[de]isoquinolin-1,3(2H)dione 3a (200 mg, 
0.74 mmol) and cinnamaldehyde (0.103 mL, 0.82 mmol) were reacted to obtain the 
title compound as an orange powder (216.2 mg, 76%); mp 196-199 °C; 1H NMR (400 
MHz, (CD3)2CO) δH 10.58 (1H, s, NH), 8.65 (1H, dd, J = 8.4 Hz, 0.8 Hz, H-7), 8.52 
(1H, dd, J = 7.2 Hz, 0.8 Hz, H-9), 8.45 (1H, d, J = 8.4 Hz, H-4), 8.23 (1H, d, J = 9.2 
Hz, N=CH), 7.75-7.71 (2H, m, H-5, H-8), 7.63-7.61 (2H, m, H-2″, H-6″), 7.43-7.39 
(2H, m, H-3″, H-5″), 7.35-7.31 (1H, m, H-4″), 7.16 (1H, dd, J = 16.0 Hz, 9.2 Hz, 
alkene α CH), 7.00 (1H, d, J = 16.0 Hz, alkene β CH), 4.09-4.05 (2H, m, H-1′), 1.72 
(2H, sextet, J = 7.6 Hz, H-2′), 0.97 (3H, t, J = 7.6 Hz, H-3′); 13C NMR (100 MHz, 
(CD3)2CO) δC 165.7 (C=O, C-1), 165.1 (C=O, C-3), 147.9 (CH, N=CH), 147.8 (quat., 
C-6), 139.2 (CH, alkene β CH), 138.4 (quat., C-1″), 135.1 (CH, C-4), 132.5 (CH, C-
9), 131.5 (quat., C-3b), 130.7 (2 × CH, C-3″, C-5″), 130.4 (CH, C-4″), 128.9 (CH, C-
7), 128.8 (2 × CH, C-2″, C-6″), 127.5 (CH, alkene α CH), 126.8 (CH, C-8), 124.8 
(quat., C-9a), 121.0 (quat., C-6a), 114.2 (quat., C-3a), 109.0 (CH, C-5), 42.9 (CH2, C-
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1′), 23.1 (CH2, C-2′), 12.8 (CH3, C-3′); FT-IR (Nujol, cm-1): 3244 (NH), 1689 (C=O), 
1639 (C=O), 1621 (C=N), 1591 (C=C), 1506 (C=C); ESI-MS: m/z 384 (MH+); Anal. 
Calcd. for C24H21N3O2.C2H5OH: C, 72.71; H, 6.34; N, 9.78. Found: C, 72.76; H, 6.41; 
N, 9.89. 
 
 
4.2.5.14 6-(2-Cinnamylidenehydrazinyl)-2-pentyl-1H-benzo[de]isoquinoline-1,3 
(2H)-dione 10b 
Using the general method, hydrazinobenz[de]isoquinolin-1,3(2H)dione 3b (200 mg, 
0.67 mmol) and cinnamaldehyde (0.093 mL, 0.74 mmol) were reacted to obtain the 
title compound as orange-red crystals (226.3 mg, 82%); mp 182-183 °C; 1H NMR 
(400 MHz, (CD3)2CO) δH 10.56 (1H, s, NH), 8.64 (1H, dd, J = 8.4 Hz, 0.8 Hz, H-7), 
8.51 (1H, dd, J = 7.2 Hz, 0.8 Hz, H-9), 8.44 (1H, d, J = 8.4 Hz, H-4), 8.22 (1H, d, J = 
9.2 Hz, N=CH), 7.75-7.70 (2H, m, H-5, H-8), 7.63-7.61 (2H, m, H-2″, H-6″), 7.43-
7.39 (2H, m, H-3″, H-5″), 7.35-7.31 (1H, m, H-4″), 7.16 (1H, dd, J = 16.0 Hz, 9.2 Hz, 
alkene α CH), 6.99 (1H, d, J = 16.0 Hz, alkene β CH), 4.12-4.08 (2H, m, H-1′), 1.74-
1.66 (2H, m, H-2′), 1.40-1.36 (4H, m, H-3′, H-4′), 0.93-0.89 (3H, m, H-5′); 13C NMR 
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(100 MHz, (CD3)2CO) δC 165.7 (C-1), 165.1 (C-3), 147.9 (N=CH), 147.8 (quat., C-6), 
139.2 (alkene β CH), 138.4 (quat., C-1″), 135.1 (CH, C-4), 132.5 (CH, C-9), 131.5 
(quat., C-3b), 130.7 (2 × CH, C-3″, C-5″), 130.4 (CH, C-4″), 128.9 (CH, C-7), 128.8 
(2 × CH, C-2″, C-6″), 127.5 (CH, alkene α CH), 126.8 (CH, C-8), 124.8 (quat., C-9a), 
121.0 (quat., C-6a), 114.3 (quat., C-3a), 109.0 (CH, C-5), 41.4 (CH, C-1′), 31.0 (CH, 
C-3′), 29.5 (CH, C-2′), 24.1 (CH, C-4′), 15.3 (CH, C-5′); FT-IR (neat, cm-1): 3269 
(NH), 1684 (C=O), 1632 (C=O), 1614 (C=N), 1570 (C=C), 1560 (C=C); ESI-MS: m/z 
411.97 (MH+); Anal. Calcd. for C26H25N3O2.C2H5OH: C, 73.50; H, 6.83; N, 9.18. 
Found: C, 73.27; H, 6.90; N, 9.36. 
 
 
4.2.5.15 6-(2-Cinnamylidenehydrazinyl)-2-benzyl-1H-benzo[de]isoquinoline-1,3 
(2H)-dione 10c 
Using the general method, 3c (200 mg, 0.63 mmol) and cinnamaldehyde (0.087 mL, 
0.69 mmol) were reacted to obtain the title compound as an orange powder (157.5 
mg, 58%); mp 232-234 °C; 1H NMR (400 MHz, (CD3)2SO) δH 11.45 (1H, s, NH), 
8.82 (1H, d, J = 8.4 Hz, H-7), 8.51 (1H, d, J = 7.6 Hz, H-9), 8.40 (1H, d, J = 8.4 Hz, 
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H-4), 8.31 (1H, d, J = 8.8 Hz, N=CH), 7.83-7.79 (1H, m, H-8), 7.65 (2H, d, J = 7.6 
Hz, H-2″, H-6″), 7.62 (1H, d, J = 8.8 Hz, H-5), 7.41 (2H, t, J = 7.6 Hz, H-3″, H-5″), 
7.35-7.28 (5H, m, H-2′, H-3′, H-5′, H-6′, H-4″), 7.23 (1H, t, J = 7.2 Hz, H-4′), 7.15 
(1H, dd, J = 16.0 Hz, 8.8 Hz, alkene α CH), 7.08 (1H, d, J = 16.0 Hz, alkene β CH), 
5.24 (2H, s, CH2); 
13C NMR (100 MHz, (CD3)2SO) δC 163.7 (C=O, C-1), 162.9 
(C=O, C-3), 146.8 (CH, N=CH), 146.4 (quat., C-6), 137.7 (quat., C-1′), 137.6 (CH, 
alkene β CH), 136.1 (quat., C-1″), 133.7 (CH, C-4), 131.1 (CH, C-9), 129.3 (quat., C-
3b), 128.8 (2 × CH, C-3″, C-5″), 128.6 (CH, C-4″), 128.5 (CH, C-7), 128.3 (2 × CH, 
C-3′, C-5′), 127.4 (2 × CH, C-2′, C-6′), 126.93 (2 × CH, C-2″, C-6″), 126.88 (CH, C-
4′), 125.5 (CH, alkene α CH), 125.0 (CH, C-8), 121.8 (quat., C-9a), 118.7 (quat., C-
6a), 110.5 (quat., C-3a), 106.8 (CH, C-5), 42.5 (CH2); FT-IR (neat, cm
-1): 3312 (NH), 
1695 (C=O), 1684 (C=O), 1636 (C=N), 1571 (C=C), 1558 (C=C), 1541 (C=C), 1508 
(C=C); ESI-MS: m/z 432 (MH+); Anal. Calcd. for C28H21N3O2: C, 77.94; H, 4.91; N, 
9.74. Found: C, 77.87; H, 4.83; N, 9.69. 
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4.3  Fluorescent experimental 
In vitro fluorescent assessment of fluorophores (3a-c: 1 × 10-4 M), protected substrates 
(4a-c: 1 × 10-4 M), substrates (5a-c: 1 × 10-4 M), and hydrazones 6-10 (6-7: 1 × 10-5 
M; 8-10: 1 × 10-4 M) in ethanol was carried out on a Shimadzu RF-5301PC 
spectrophotometer using identical scan parameters, utilizing a 5 mm slit width, if not 
stated otherwise.  
  
4.4  Microbiology 
4.4.1 Preparation of culture media containing substrates 5a-c 
1 L of Columbia agar was prepared as follows; 41 g of Columbia agar (Oxoid 
Basingstoke, UK) was dissolved by boiling in 1 L of distilled water. The solution was 
then sterilized by autoclaving at 116 °C for 20 minutes and left to cool at 50 °C. 2 mg 
of each substrate 5a-c to be tested was initially dissolved in 100 μL of N-
methylpyrrolidine and this was added to Columbia agar (made up to 20 mL), then 
poured into sterile Petri dishes to give a final concentration of 100 mg/L for the 
substrates 5a-c. Columbia agar mixed with N-methylpyrrolidine was used as a growth 
control.  
 
4.4.2 Microbial suspension preparation 
Microbial reference strains were obtained from either the National Collection of Type 
Cultures (NCTC) or the National Collection of Pathogenic Fungi (NCPF) which are 
both located at the Central Health Protection Agency Laboratory, Colindale, UK or 
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the American Type Culture Collection (ATCC), Manassas, USA. The 20 test 
microorganisms were maintained on Columbia agar. 
 
4.4.3 Multipoint inoculation 
Colonies of each microbial strain were harvested using a loop from overnight cultures 
on Columbia agar. These were suspended in sterile deionized water to a suspension 
equivalent to 0.5 McFarland units using a densitometer. 100 μL of this suspension was 
pipetted into the corresponding wells of a multipoint inoculation device. Each set of 
plates received 1 μL of bacterial suspension, giving 1.5 x 105 organisms per spot on 
each inoculation. Twenty strains were inoculated per plate and the plates were 
incubated for 18 h in air at 37 °C. 
 
4.4.4 Activity determination 
After incubation, the activity of the microorganisms with the test substrates was 
determined by observing the plates under UV irradiation at 365 nm and comparing 
with the substrate-free control. The presence of fluorescence emission was considered 
as positive evidence for the hydrolysis of the substrate by β-alanyl aminopeptidase. 
. 
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